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ABSTRACT
ENGINEERING OF ESCHERICHIA COLI 2-OXOGLUTARATE
DEHYDROGENASE COMPLEX WITH MECHANISTIC AND SYNTHETIC GOALS
by
Joydeep Chakraborty
The Escherichia coli 2-oxoglutarate dehydrogenase complex (OGDHc) compromises multiple
copies

of

three

enzymes

-

2-oxoglutarate

dehydrogenase

(E1o),

dihydrolipoyl

succinyltransferase (E2o), and dihydrolipoyl dehydrogenase (E3). OGDHc is found in the
Krebs cycle and catalyzes the formation of the all-important succinyl-Coenzyme A (succinylCoA). OGDHc was engineered to understand the catalytic mechanism and optimized for
chemical synthetic goals.
Succinyl-CoA formation takes place within the catalytic domain of E2o via a
transesterification

reaction.

The

succinyl

group

from

the

thiol

ester

of

S8-

succinyldihydrolipoyl-E2o is transferred to the thiol group of CoA. Mechanistic studies were
designed to investigate enzymatic transthioesterification. His375 and Asp374 was shown to be
important in E2o. The magnitude of the rate acceleration provided by these residues suggests
a role in stabilization of the symmetrical tetrahedral oxyanionic intermediate by formation of
two hydrogen bonds, rather than in acid–base catalysis. Further evidence ruling out a role in
acid–base catalysis is provided by saturation mutagenesis studies at His375 and substitutions
to other potential hydrogen bond participants at Asp374. The rate constant for reductive
succinylation of the E2o lipoyl domain (LDo) by E1o and 2-oxoglutarate (99 s-1) was
approximately twofold larger than the rate constant for kcat (48 s-1) for the overall reaction
(NADH production). It could be concluded that succinyl transfer to CoA and release of
succinyl-CoA is the rate-limiting step. The results suggest a revised mechanism of catalysis for
acyl transfer in the superfamily of 2-oxo acid dehydrogenase complexes, thus provide

fundamental information regarding acyl-CoA formation, so important for several biological
processes including post-translational succinylation of protein lysines.
OGDHc was converted from a 2-oxoglutarate dehydrogenase to a 2-oxo aliphatic
dehydrogenase complex by engineering consecutive components. OGDHc was reprogrammed
to accept alternative substrates by evolving the E1o and E2o components. Wt-ODGHc does
not accept aliphatic substrates. E1o was previously engineered to accept a non-natural aliphatic
substrate, 2-oxovalerate (2-OV). E2o also required engineering to accept 2-OV in the overall
reaction. Hence, saturation mutagenesis libraries of E2o were screened and several variants
were identified for 2-OV activity. Variants also displayed activity for larger aliphatic
substrates, which demonstrates the potential green synthetic utility.
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CHAPTER 1
INTRODUCTION

1.1 2-Oxoglutarate Dehydrogenase Complex
The 2-oxoglutarate dehydrogenase complex (OGDHc) or α-ketoglutarate dehydrogenase
complex is most commonly known for its role in the Krebs cycle. This enzyme belongs to
a family of multienzyme complexes. They are classified on the natural substrate
(pyruvate, 2-oxoglutarate (2-OG) or branched-chain α-keto acids) that they utilize (Figure
1.1) [1].

Figure 1.1 α−Keto acid substrates.
This family of multienzyme complexes is important in controlling the carbon flux
from carbohydrate precursors and a select group of amino acids into and around the
Krebs cycle (Figure 1.2) [2]. This enzyme complex catalyzes the non-equilibrium
reaction converting 2-ΟG, Coenzyme A (CoA) and NAD+ to succinyl-CoenzymeA
(succinyl-CoA), NADH and CO2.

1

Figure 1.2 Krebs Cycle.

Figure adaptation: Jeremy M. Berg, John L. Tymoczko, and Lubert Stryer Biochemistry, 8th edition, 2015
pp 509 figure 17.15.

The overall reactions require three protein components, which is comprised of a
substrate specific dehydrogenase/decarboxylase (E1o EC 1.2.4.2, Figure 1.3a), dihydrolipoamide succinyl transferase (E2o EC 2.3.1.6, Figure 1.3b), and dihydrolipoamide
dehydrogenase (E3 EC 1.8.1.4, Figure 1.3c). The above enzymes respectively require the
cofactors thiamine diphosphate (ThDP), lipoic acid and flavin adenine dinucleotide
(FAD). In Escherichia coli, E1o and E3 exist as homodimers. The E2o component is a
trimeric multidomain protein, starting with the amino terminal end a flexible lipoyl
2

domain (LDo), followed by a long mostly unstructured subunit binding domain for
assembly with E1o/E3, then a central nexus catalytic core domain (CDo). The enzyme
complex is inhibited by its end products, succinyl-CoA and NADH. It is also regulated by
the ATP/ADP ratio, the NADH/NAD+ ratio, calcium and the substrate availability in the
cellular environment [3,4].

Figure 1.3 Ribbon diagrams for OGDHc components: A. Structure of a truncated variant
of E1o (tE1o) that is missing the first 77 amino acids on the N-terminus (PDB ID: 2JGD).
The structure of tE1is homodimer and each chain (105 kDa/subunit) is represented as
gold and green ribbons. B. NMR structure of E2o lipoyl domain (21 kDa) (PDB ID:
1PMR). C. Catalytic domain of the E2o is shown as a trimer with each chain (45
kDa/subunit) represented in red, yellow and maroon ribbons (PDB ID: 1C4T).
D. E3 is shown as a homodimer (55 kDa/subunit) (PDB ID: 4JDR).
1.2 Structural Assembly
The quaternary organization of the OGDHc ensures that the products of one reaction are
efficiently shuttled to the next active site for the subsequent reaction (called substrate
channeling). In almost all instances, E1o and E3 are recruited into their multienzyme
complexes through direct interaction with E2o, which is an oligomeric enzyme with
structurally distinct domains that are linked by flexible regions [5]. OGDHc complexes
are assembled in a tight but noncovalent fashion. This multicomponent and multimeric
3

nature results in the formation of relatively large complexes with an approximate mass of
2.5 MDa [6,7]. In E. coli, the assembly of OGDHc is organized around a 24-meric
central core of E2 that exhibits octahedral symmetry (Figure 1.4). The oligomeric E2 core
is responsible for tethering and orientating both the E1o and E3 enzymes within the
complexes via compact, peripheral subunit-binding domains. The organization of the
three component enzymes is crucial for the activity of the complex. The proposed
stoichiometry for the E. coli complex has been estimated at 12 E1o : 24 E2o : 12 E3. The
oligomeric E2o forms the foundation, and it is bound to multiple copies of E1o and E3
[6,8,9].

Figure 1.4 Schematic representation of assembled 2-oxoglutarate dehydrogenase
multienzyme complex consisting of multiple copies of E1o, E2o and E3 [10].

Figure adaptation: Reginald H. Garrett, Charles M. Grisham Biochemistry, 6th edition, 2017 pp 670 figure
19.21.

4

1.3 OGDHc Overall Reaction
The overall reaction of OGDHc is as follows (Equation 1.1):
2-oxoglutarate + NAD+ + CoA → succinyl-CoA + CO2 + NADH + H+

(1.1)

The steps of the overall reactions are shown in Figure 1.5.
Step 1: E1o component catalyzes the initial decarboxylation of the 2-oxoglutarate, using
ThDP as a cofactor.
Step 2: This step is followed by reductive succinylation of the lipoyl group bound to the
ε-amino group of a lysine residue in E2o.
Step 3: E2o is a succinyl transferase responsible for transferring the succinyl group to
CoA.
Step 4: The reduced dihydrolipoyl group left on E2o is reoxidized to the dithiolane ring
by the flavoprotein E3, with NAD+ as the ultimate proton acceptor [11].

Figure 1.5 The overall reaction mechanism of the complex.
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1.4 E1o Component
The

thiamin

diphosphate

(ThDP)

dependent

E1o

component

is

a

dehydrogenase/decarboxylase enzyme. The crystal structure of apo-E1o has been solved
to 2.6 Å, and it reveals that the enzyme in E. coli is a homodimer (α2) [12]. The crystal
structure (Figure 1.3A) depicts a 190 kDa truncated E1o lacking the first 77 residues
from its N-terminus. The truncated enzyme retains decarboxylase activity but it does not
form a complex with E2o, suggesting the importance of the N-terminus for E1o-E2o
interactions [12]. The E1o active site is lined by three histidine residues at positions 260,
298 and 729 and a serine at position 302 (Figure 1.6). The residues have been proposed to
be responsible for substrate specificity. Their proximity to the ThDP thiazolium ring
make them likely to define the substrate binding pocket or be of catalytic importance
[12,13].

Figure 1.6 Active site of E1o. The active site residues His260, His298 and Ser 302 of
chain A (cyan) and His729 of chain B (red) have been shown (PDB ID: 2jgd).
6

In the active site, the catalytic mechanism has been proposed based on the two
histidines at 260 and 298 which behave as a general acid-base catalyst. Substrate
channeling occurs through an acidic channel that serves as a proton wire. The catalytic
rates of E1o were greatly reduced upon substitution of alanine in place of the His260 and
His298, that proved their importance in the reaction [12]. This is consistent with their role
in recognition of the distal carboxylate of 2-OG. Previously, the program to alter the
substrate specificity of OGDHc to utilize it as a catalyst for green chemical synthesis was
initiated by engineering the active site of E1o. In OGDHc, there are three levels of
substrate specificity. One occurs at the E1o level and the other two at E2o (LDo and
CDo). The active site histidines at 260 and 298 of E1o were identified by structural data
as important residues for binding and activity [13]. The goal was to engineer the enzyme
to accept a non-natural substrate 2-oxovaleric acid (2-OV). This substrate is a homolog of
2-OG (Figure 1.1), but it lacks the distal carboxyl group (Figure 1.1). The libraries
His260X, His298X and His260X/His298X were constructed by saturation mutagenesis
and screened for activity towards 2-OV as substrate. Active mutants were identified
using a E1o-specific assay (Figure 1.7). The assay is a direct measure of the
decarboxylase

activity

of

E1o

by

an

external

oxidizing

agent

2,

6-

dichlorophenolindophenol (DCPIP). Reduction of DCPIP is determined by the loss of
absorbance at 600 nm [14] and affirms that decarboxylation to the enamine had taken
place.
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Figure 1.7 DCPIP, an E1-specific, assay reaction.
Results showed that His260 was crucial for substrate binding and most likely has a
hydrogen bonding role. The His298 residue when replaced with leucine, threonine,
valine or aspartate were all shown to decarboxylate 2-OV (Figure 1.5, Step 1). The E1oHis298Asp was the most active variant showing improvements of catalytic efficiency
over the wild type enzyme towards 2-OV [13]. However, NADH production could not
be detected in the overall reaction. Mass-spectrometric evidence also showed that there
was successful transfer of the E1o-bound hydroxybutyl-ThDP intermediate of substrate
(2-OG/2-OV) to the E2o-LDo. This indicated at the E2o level, the second substrate
checkpoint, where the succinyl group is transferred from the S-atom of dihydrolipoamide
to the S-atom of CoA was blocked towards synthesis of the acyl-CoA derivative derived
from 2-OV.
Further, hybrid complexes were also constructed consisting of components from
both the OGDHc and the pyruvate dehydrogenase complex (PDHc). The results
suggested different components acting as ‘gate-keepers’ for the specificity for these two
multienzyme complexes in E. coli. It was shown that E1p determined specificity for
pyruvate. However, the same specificity towards 2-OG is determined by E1o and E2o
[13].
From this information, it was evident that engineering E2o was necessary to bypass
its substrate checkpoint. To broaden the scope of efforts to produce acyl-CoA analogues
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and use OGDHc as a synthetic tool, the mechanism at the active site of the catalytic core
domain of E2o was further investigated. Also, it was essential to understand the structurefunction relationship of the E2o active site residues that contribute to the catalysis of the
succinyl-transfer reaction.

1.5 E2o Component
The E2o component consists of, from N-terminal, lipoyl domain, subunit binding
domain, and a catalytic domain. The number of lipoyl domains can vary between 1 to 3,
which depends on the organism. The domains are connected by flexible linker segments.
In E. coli, the E2o component consists of only one lipoyl domain (LDo), followed by one
E1 and/or E3 binding domain (peripheral subunit binding domain or PSBD), and then
by a carboxyl-terminal catalytic or core domain (CDo) (E2oec) [15] (Figure 1.8). The
E2o is organized as a 24-mer with octahedral symmetry [16].

The flexibility of the

linker segments is thought to inhibit crystallization of the native E2o. Despite that,
significant amount of structural information has been published from individual domains
(Figure 1.8) [17].

Figure 1.8 Schematic representation of the domains of the E2o component of E. coli.

The ditholane ring of the flexible lipoyl-lysine arm has been shown on the lipoyl domain (yellow). The
value of n = 1, 2 or 3 depends on the organism. For E. coli, n = 1. The lipoyl domain is followed by the
peripheral subunit binding domain (PSBD) represented in orange. The final catalytic core domain is
represented in green.
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1.6 E3 Component
The third component of OGDHc is E3 or dihydrolipoamide dehydrogenase. E3 is a
flavoprotein that binds FAD and NAD+ and it is shared between OGDHc and PDHc, and
in fact all such complexes in a particular cell share the same E3. In E. coli, the E3
interacts with E2o non-covalently at the PSBD. The role of E3 is to reoxidize the
dihydrolipoamide of E2o LDo after succinyl transfer (Figure 1.5, Step 3) [18]. Thus, the
E3 restores the initial redox states of the E2o LDo lipoamides allowing the multienzyme
complex to cycle (Figure 1.5, Step 4). In the other half of the redox reactions, E3 reduces
NAD+ to NADH (Figure 1.9 and Figure 1.5, step 4) [19].

Figure 1.9 E3 catalyzes the restoration of the redox states of the cofactors and the E2
component.
1.7 Applications of OGDHc
1.7.1 As an enzyme for green synthesis
The pharmaceutical, food, detergent, and biofuel industries have reaped the advantages of
enzyme catalysis in commercial-scale applications. For complex chemical reactions, the
most significant advantages that enzyme catalysis holds over chemical catalysis are the
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high regio-, chemo-, and stereoselectivities at which enzymes convert substrate to
product [20]. This is the advantage in biological systems; however, they may not be
suited for industrial applications. A few common examples of industrially applied
enzymes are trypsin, amylase, laccase and lipase in food processing and detergent
industries [21–24]. In the pharmaceutical industry, an example of enzyme catalyzed
synthesis is sitagliptin, a drug marketed by Merck for type II diabetes treatment [25,26].
The conventional synthesis requires heavy metals, extreme reaction conditions and
suffers from low yields. Hence, an R-selective transaminase was evolved to catalyze the
synthesis with 99.95% e.e. in organic solvent [27–29].
An important example of an intermediate in the organic chemistry and drug
industries is CoA linked thioesters. Acyl-CoA and its analogs are important products of
α-ketoacid dehydrogenase class of enzymes, such as OGDHc. CoA derivatives are
essential and found as intermediates at the crossroads of a variety of metabolic pathways.
For example, acetyl CoA is an important link between glycolysis and Krebs cycle [30].
CoA forms thioester linkages with α−keto acid substrates and its terminal thiol. The
reactivity of CoA thiol or thioester is diverse. Thiol has a relatively high pKa (9-10),
which makes them good nucleophiles.

On the other hand, thioesters are good

electrophiles for alcohols, amines, and enolates. Furthermore, a thioester can serve as a
nucleophile in its enolate form. This duel character provides versatility for CoA as a
cofactor in nature [31]. CoA – linked thioesters can be used as intermediates for organic
synthetic purposes. For example, they are precursor to their corresponding carboxylic
acid derivatives [32]. Furthermore, they are also key intermediates for peptide coupling
[33–35], acyl transfer [36,37], thiol protecting strategies [38] and in organometallic
reaction coupling [39]. CoA thioesters are important molecules in the pharmaceutical
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industry as reactivity probes, as enzyme inhibitors and as reporter labels [40]. Traditional
organic synthetic pathway for acylation of thiols involve the use of acyl sources from
carboxylic acids, acid anhydrides or acid chlorides. The reactions proceed in the presence
of strong bases such as ethylamine, pyridine or DMAP for refluxing for several hours.
The reactions are also supplemented with suitable catalysts such as triflates, CsF, NBS,
zeolites,

rongalite,

lanthanum(III),

isopropoxide,

Lewis

acids,

zinc

lithium,

bis(perfluoroalkylsulfonyl)imide, ionic liquids, titanocene bis(perfluorooctanesulfonate)
and dodecylbenzenesulfonic acid for the acylation of thiones. [41]. In conclusion, the
synthetic routes are multistep, energy intensive and involve extreme reaction conditions
that can be possibly hazardous to the environment.
OGDHc catalyzes the rate limiting step of the Krebs cycle, which is succinyl CoA
formation from 2-OG (Figure 2) [2]. As a CoA-dependent enzyme complex it uses the
cofactor to bind to carboxylic acids, which are involved in primary and secondary
metabolism [31]. OGDHc is able to perform trans-thioesterification as a natural reaction,
which is chemically difficult to achieve. The final product of this reaction is a CoAlinked thioester (succinyl-CoA) which is of much interest in pharmaceutical and chemical
industries. This makes OGDHc a suitable candidate for one-pot multistep green chemical
synthesis under much milder aqueous conditions, thus providing a sustainable and green
synthetic chemical pathway. However, being part of a conserved metabolic pathway,
such as the Krebs cycle, OGDHc has high substrate specificities at multiple levels at the
constituent components. Thus, optimization of the complex is required, to implement it at
an industrial level.
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1.7.2 Enzyme optimization and engineering
Enzymes catalyze highly specific reactions under mild conditions in aqueous solutions.
Therefore, enzymes can be used for environmentally friendly chemical synthesis.
However, they require engineering and optimization for industrial process conditions,
such as thermostability, organic solvent resistance or altered substrate specificity.
Enzyme properties are not coupled. For example, altering the substrate specificity may
come at the cost of thermostability. This is especially true for enzymes of conserved
pathways, that have specific functions across many species [42,43]. Although the activity
and many other properties can be enhanced by accumulation of beneficial mutations over
generations of random mutagenesis and screening, it was once believed that it was
impossible

to create completely novel catalytic activity [44]. One of the earliest

approaches to modify enzyme specificity was by rational design [45–47]. This requires
in-depth knowledge of crystal structure of the protein and active site configurations.
However, the complexity of structure-function relationship of enzymes is a critical
limitation to this approach. It is found that enzyme modifications that enhance certain
enzyme properties, such as substrate specificity or new catalytic activity, can be located
near the active site [48–52]. However, other mutations beneficial for properties such as
stability or activity may be far from the active site. It has also been shown that mutations
far from the active site can contribute to substrate specificity [53–55]. These mutations
would be impossible to predict from rational design.
Directed evolution breaks through this barrier. This idea mimics natural evolution
on a single molecule level. First, a parent gene is used to create a library with random
mutations. Next, a screening or selection is used to identify protein variants with the

13

desired properties. Then, the gene is isolated, and it is used as the parent for the next
round of laboratory evolution until the optimization is achieved (Figure 1.10).

Figure 1.10 Schematic representation of Directed evolution method to evolve proteins.
The major advantage of directed evolution is rapid engineering of enzymes
without in-depth structural knowledge. One of the earliest examples was subtilisin
evolution in a polar organic solvent dimethyl sulfoxide [56,57]. The final variant had a
~471 fold increased activity over the wild-type under similar conditions [58]. The
potential of directed evolution is to be used as a tool to manipulate proteins towards
performing reactions that are absent in the biological world. For example, enzymatic
formation of carbon-silicon bonds was achieved. This reaction is not found in any
biological system. Cytochrome C was evolved to catalyze formation of carbon-silicon
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bonds with an efficiency of ~15 times over the best chemical catalyst used for the
purpose [59]. In nature, cytochrome C is an electron carrier in the electron transport
chain, and it does not perform any catalytic reactions. Rational and directed evolution can
complement each other in an engineering strategy. Structure/function knowledge can be
used to create focused libraries [60]. For example, saturation mutagenesis can used.
Saturation mutagenesis is a method to mutate any amino acid simultaneously to all other
19 amino acids.

1.7 Thesis Objectives
1.
Characterization of the critical residues in the active site of E2o catalytic domain
that contribute to catalysis and elucidate the mechanism of the succinyl transfer reaction.
The main goal is to understand the contribution of the catalytically important residues in
the E2o catalytic domain. It has been established that the human OGDHc activity is
linked to Alzheimer’s and Parkinson’s diseases [61], besides its contribution to cellular
disorders related to oxidative stress. The E2o catalytic domain is conserved in all life
forms. Mechanistic knowledge provides molecular details of metabolic pathways and the
underlining cause of disease.

2.
Altering substrate specificity of OGDHc and convert 2-oxo acid to a 2-oxoaliphatic acid dehydrogenase complex by engineering E2o.
An important application of OGDHc, is its ability to perform a complex acyl transfer
reaction and produce succinyl-CoA. CoA-linked thioester chemical synthesis is a
multistep process. Engineered recombinant OGDHc can potentially replace existing
synthetic methods with a green method to generate the desired thioester analogs.
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CHAPTER 2
CATALYSIS OF TRANS-THIOACYLATION IN THE ACTIVE CENTERS OF
DIHYDROLIPOAMIDE ACYLTRANSACETYLASE COMPONENTS OF
2-OXO ACID DEHYDROGENASE COMPLEXES

2.1 Introduction
In the Krebs cycle, the 2-oxoglutarate dehydrogenase complex (OGDHc) catalyzes one of
the most important steps, converting 2-oxoglutaric acid (2-OG) to succinyl CoA. OGDHc
is

composed

of

multiple

copies

of

three

components:

(i)

2-oxoglutarate

dehydrogenase/decarboxylase (E1o), (ii) dihydrolipoamide succinyl transferase (E2o) and
(iii) dihydrolipoamide dehydrogenase (E3). The key metabolic product succinyl-CoA is
produced from the catalytic domain of the E2o. In Escherichia coli, E2o is a multidomain
enzyme: proceeding from the N-terminus it consists of a lipoyl domain(s) (LDo) (~85
amino acids), a peripheral subunit binding domain (PSBD) (~48 amino acids) and a
catalytic core domain (CD) (~231 amino acids). The E2o core is composed of 24
subunits that are organized with a 432 point group symmetry, to which both E1 and E3
dimers are attached tightly and non-covalently [1-4]. The organization of the E2 core in
OGDHc is specific for each organism [5]. The domains E2o are linked together by
flexible 25–30 residue segments rich in alanine, proline, and charged amino acids
[62,63]. Chapter 1 outlines the structural organization of the overall complex along with
the role of the individual components in the overall reaction. In the current chapter, the
kinetic parameters of E2o have been determined to characterize catalysis at the active site
of the enzyme.
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2.2 E2o Domains
2.2.1 Role of the lipoyl domain
The lipoyl domain is the site of attachment of the prosthetic group, lipoic acid. The
attachment of the lipoyl group to the conserved Lys43 at the tip of the protruding β-turn,
gives a domain flexibility and reach to the active centres of E1 and E3 (Figure 2.1) [64].

Figure 2.1 General mechanism of the lipoyl domain accessibility to the active sites of E1
and E3 for 2-oxoacid dehydrogenase complexes [65].
The flexible lipoamide arm of the lipoyl domain is able to transport the decarboxylated acyl intermediate
from E1 (turquoise) active site to the E2 catalytic domain (green). In the E2CDo, the acyl group is
transferred to CoA forming Acyl-CoA. The dithiolane ring of the lipoamide arm gets re-oxidized at E3
(yellow).

The number of lipoyl domain varies from one to three depending on the enzyme
complex. In Escherichia coli the OGDHc has one lipoyl domain while pyruvate
dehydrogenase complex (PDHc) has three [62]. An individual lipoyl domain carries a
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lipoyl group in amide linkage with the N-6 amino group of a specific lysine residue
forming the swinging arm that ferries substrate (Figure 2.2) [66]. This attachment also
limits the diffusion of the dithiolane ring. Only R-enantiomers of the lipoate and
dihydrolipoate function with the OGDHc. It is essential for the lipoyl group to be
attached to the lipoyl domain for the reductive acylation reaction by the dithiolane ring
[11,66]. The ring is at the end of a 1.4 nm swinging arm and is free to rotate with respect
to the bulk of the protein.

Figure 2.2 Structure of lipoyl domain with the attached lipoyl moiety.

The green ribbon represents a single chain of the lipoyl domain of E.coli E2o. The NMR structure is
derived from PDB entry 1PMR. The lipoate moiety is shown to be attached with the Lys43 residue of the
lipoyl domain. The 1.4nm flexible arm has a dithiolane ring at the end of it.

The enzymes trypsin and lipoamidase have been used as probes to examine the
correlation between loss of lipoyl domains or lipoyl moieties versus the loss of overall
activity for PDHc and OGDHc. Trypsin digest releases the lipoyl domains that are
covalently attached with the lipoyl moieties. In contrast, lipoamidase releases the lipoyl
moiety from the lipoyl domain. The results showed that the rate of release of lipoyl
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domains (tryptic digests) or lipoyl moieties (lipoamidase digest) was higher than the
corresponding rate of loss of overall activity [63,67].
The flexibility of the lipoyl domain confers some process of molecular recognition
and interaction between LDo and its cognate E1o component [5]. In recent years, the
Farinas and Jordan groups have undertaken studies of the E. coli 2-oxoglutarate
dehydrogenase complex (OGDHc) with a view to expand the substrate range of the
complex and utilize it for green chemo-enzymatic synthesis. The active site of E1o was
engineered to accept the non-natural substrate 2-oxovaleric acid (2-OV). However, the
overall reaction of the complex did not produce NADH or butyryl-CoA. Massspectrometric evidence showed that the E1o active center could reductively acylate the
lipoyl domain. This indicated an apparent checkpoint regulation at the active site of E2o
catalytic domain. Hybrid complexes with different components of PDHc (E1p, E2p and
E3) and OGDHc (E1o, E2o and E3) revealed that E1o could reductively acylate the
lipoyl domains of both E2p and E2o. This property was absent in E1p. Hence, it was
concluded that substrate recognition occurs at E1p for PDHc and at E1o, E2oLDo and
E2oCD for OGDHc [13]. To broaden the synthetic versatility to produce acyl-CoA
analogues, it was necessary to bypass the E2o checkpoint. A mechanistic role is proposed
for the key catalytic residues at the active site of E2oCD.
2.3 The Catalytic Core Domain of E2o
2.3.1 Active site of E2o core domain
The E2o structure has not been determined. However, the structure of a truncated form
(tE2o) from E. coli has been solved to a 3.0 Å resolution. The tE2o structure lacks most
of the N-terminal and peripheral domains [9,68]. The E. coli E2oCD topology is highly
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similar to that of another well-known enzyme of the acyl-transferase family, the
chloramphenicol acyl transferase (CAT; EC 2.3.1.28)[69] and A. vinelandii E2pCD [15,
16]. Conserved amino acids were found from sequence alignments from various
organisms [17].
Structural homology and crystallographic data of CAT and E2oCD suggested a
general mechanism of the succinyl transferase reaction occurring at the active site. Also,
residues involved in catalysis in the active site had been predicted [71]. An active site
histidine (His375) was proposed to be a general-base catalyst. In the first step, His375
was suggested to deprotonate the thiol group of coenzyme A (CoA-SH) [16]. Next, CoAS- would attack the carboxylate of the acylated lipoyl moiety (from LDo) to form a
tetrahedral intermediate. The collapse of this intermediate results in the transfer of the
acyl group to CoA-S-. The tetrahedral intermediate is stabilized by a threonine residue
(Thr323). In addition, an aspartic acid residue (Asp379) assists in the stabilization of the
correct tautomer of the catalytically essential histidine (vide infra).
The side chain of His375 is oriented 2.5 Å apart with respect to the Thr323 (Figure
2.3b). A salt bridge between Asp374 and Arg376 on the same loop as His375, stabilizes
the enzyme-substrate complex. In the E2oCD-CoA complex, the conformation changes
the orientation Asp379 to interact with His375 and form a salt bridge with Arg184 of a
neighbouring residue. In addition, the side-chain of Arg376 is positioned so that a single
hydrogen bond is formed with Asp374 (Figure 2.3b)[16].
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Figure 2.3 a, Ribbon drawing showing the crystal structure of the truncated E2o
Catalytic Domain trimer with each subunit in a different color ribbon [16]. The three
chains of the trimer, viz, chain a, chain b and chain c are represented by red, green and
cyan respectively. b, active site region at a trimeric subunit interface within the trimer
showing positions of active site residues Thr323, Asp374, His375, Arg376 and Asp379
on chain b is shown (PDB ID:1C4T).
2.3.2 Mechanism of the succinyl transferase reaction at the E2o core
Structural homologies
In the superclass family of acyl transferases, sequence alignment studies have been
carried out between E2o and E2p derived from the sucB and aceF genes, respectively.
The active site mechanism of these enzymes have been proposed based on their sequence
homologies with CAT [71]. The CAT catalyzes the O-acetylation of chloramphenicol in
antibiotic resistant bacteria [72,73]. A common feature amongst the CAT, E2o and E2p
active sites is the presence of a conserved motif sequence containing the catalytic
histidine: His-x-x-x-x-Asp-Gly-x-His (where, x is any amino acid residue).
The catalytically important His375 has been identified in E2o and His602 for E2p,
corresponding to the catalytic His195 in CAT (Figure 2.4). The latter has been
extensively studied and kinetically characterized by Shaw and Leslie [74,75].
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Figure 2.4 Comparison of the crystal structure of monomeric chloramphenicol acetyl
transferase (PDB ID: 1CIA) and E2o dihydrolipoamide succinyl transferase catalytic
domain, chain a (PDB ID: 1C4T).
The crystal structure superposition of CAT and E2oCD reveals catalytic His195 and Asp199 are located on
the same loop for CAT as the corresponding His375 and Asp379 for E2oCD.

2.3.3 Comparative acyl transfer mechanism site of the acyltransferase superfamily
The role of the active site histidine E2o-His375 has been predicted based on CATHis195, which serves as a general base. Evidence of formation of hydrogen bond
between N-1 proton of His195 and the carboxylate of another conserved aspartate residue
(Asp199) had been reported [75]. This confers tautomeric stabilization that possibly
allows the electron pair at N-3 to abstract a proton from the 3-OH group of
chloramphenicol to promote a nucleophilic attack on the thioester of CoA (Figure 2.5, for
CAT) [76]. A similar mechanism had been proposed for E2oCD active site catalysis. The
conserved E2o-Asp379 plays a similar role as CAT-Asp199 (Figure 2.4). The N-3 of
His375-imidazole abstracts a proton from CoA-SH. This triggers the nucleophilic attack
on the carbonyl carbon of the dihydrolipoamide succinyl group. This forms the
tetrahedral oxyanionic intermediate which is stabilized by a third catalytic residue Thr323
(Figure 2.5 for E2oCD) [71].
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Figure 2.5 Top. The proposed mechanism involving the catalytic His375 at the active site
of E2o core domain. His375 is proposed to be a general base catalyst in the succinyl
transferase reaction.
Bottom. The mechanism of catalytic His195 at the active site of chloramphenicol acyl
transferase. His195 is a general-base catalyst in the acyl-transferase reaction [16,72].

2.4 Importance of Studying the E2o-Active Site Mechanism and
the Objectives of this Study
Recent studies revealed multiple roles for the mitochondrial OGDHc, and a better
understanding of their mechanism could be important for bringing new insight into
human diseases. The unique property of the mitochondrial OGDHc to produce the
reactive oxygen species superoxide and hydrogen peroxide (H2O2) from its substrate 2OG had been attributed earlier to the flavin cofactor tightly bound to the E3 component
[77,78]. Jordan group studies revealed that human E1o (hE1o) can produce the ThDPenamine radical and superoxide anion from 2-OG and from the next higher homologue 2oxoadipate (2-OA) by one-electron oxidation of the ThDP-enamine intermediate with
dioxygen [79,80]. The efficiency of superoxide/H2O2 production by OGDHc was 7 times
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larger from 2-OA than from 2-OG making the OGDHc one of the important reactive
oxygen species producers among 2-oxo acid dehydrogenase complexes in mitochondria
[78,80].
In a role different from its role in the TCA cycle, the OGDHc could also serve as a
producer of succinyl groups in neurons and neuronal cell lines for reversible posttranslational modification of the cytosolic and mitochondrial enzymes, including those
from the TCA, by succinylation, hence playing a role in neurodegenerative diseases [81].
The post-translational modification of histone proteins by succinylation is regarded as
very important because it can directly regulate gene expression [82,83]. Recently,
evidence of the interaction between the nuclear OGDHc and lysine acetyltransferase 2A
displayed a role of lysine acetyltransferase as a carrier of succinyl groups produced by
nuclear OGDHc for direct histone H3 succinylation [82].
Studies from the Jordan group suggested that human 2-oxoadipate dehydrogenase
(hE1a, also known as DHTKD1-encoded protein), which is involved in the oxidative
decarboxylation of 2-oxoadipate to glutaryl- CoA on the final degradative pathway of Llysine, L-hydroxylysine, and L-tryptophan, has recruited the hE2o and hE3 components
of the OGDHc for its function [84]. In other words, the hE2o could serve as a source of
both succinyl-CoA and glutaryl-CoA in mitochondria and could be linked to the lysine
post- translational modification by glutarylation earlier reported [85].
The enzymatic mechanism being studied in this research is responsible for
synthesis of important acyl- CoA metabolites involved in post-translational modification
of proteins. The results provide important baseline residue-specific contribution to
catalysis of succinyl-CoA formation in the active center of the E. coli E2o that would be
applicable to all E2o components due to high sequence identities reported for all E2o
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core/catalytic domains [16,17,19,70,86–88]. The major goal of this study was to address
the role of the highly conserved His375 in the active center of the E. coli E2o. The
His375Ala substitution was found to decrease the catalytic efficiency (kcat/Km, 2-OG) by
54-fold compared to unsubstituted E2o. This value was approximately 10 000 times
smaller than that deter- mined on Ala substitution of the corresponding His195 in
chloramphenicol acetyltransferase (CAT, kcat/Km = 53 x 10-4-fold smaller for the
His195Ala variant than wild-type) [75], placing in doubt the earlier deduction of an acid–
base catalyst role of His375, assigned by comparison with CAT [71,89]. To gain more
insight regarding the function of His375, site-saturation mutagenesis was carried out at
this residue, whose results suggested that the His375Trp and His375Gly substitutions at
E2o were acceptable, reducing the catalytic efficiency only by two- and five- fold,
respectively. Similarly, the Asp374Asn substitution in the E2o active center (10 times
less efficient variant) rescued some of the activity displayed by the Asp374Ala
substitution (54-times less efficient variant), consistent with participation of Asp374 in
hydrogen bond formation. The totality of the current studies suggested that there is no
proton transfer in the rate-limiting step in which both His375 and Asp374 participate
(Figure 2.6); rather, they may stabilize by hydrogen bonds a transition state, probably
resembling a tetrahedral oxyanionic intermediate.
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Figure 2.6 Mechanism of 2-oxoglutarate dehydrogenase complex and the putative
oxyanionic tetrahedral intermediate suggesting the role of His375 and Asp374 in E2o
active center [90].
2.5 Materials and Methods
2.5.1 Reagents
Dithiothreitol (DTT), 2-oxoglutarate, 2-oxovalerate, 2-oxoadipate, and pyruvate were
from

Sigma-Aldrich

(St.

Louis,

MO,

USA).

NADH,

CoA,

isopropyl-β-D-

thiogalactopyranoside (IPTG), DNase I, micrococcal nuclease, DL-α-lipoic acid, and
ThDP were from Affymetrix (Cleveland, OH, USA). Protease inhibitor cocktail tablets
were from Roche Diagnostics GmbH (Mannheim, Germany). Ni-Sepharose 6 Fast Flow
and HiPrepTM 26/60 SephacrylTM S-300 HR column were from GE Healthcare
(Pittsburgh, PA, USA). QuikChange Site-Directed Mutagenesis Kit was from Agilent
Technologies (Santa Clara, CA, USA). Primers for site-directed mutagenesis were from
Fisher Scientific (Pittsburgh, PA, USA). Escherichia coli strain JW0715 containing the
pCA24N plasmid encoding the E1o component and JW0716 containing pCA24N plasmid
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encoding the E2o component were obtained from National Bio Resource Project (NIG,
Japan). AG1 cells (Agilent Technologies) were used as host cells.

2.5.2 Protein Expression and Purification
2.5.2.1 Expression and purification of E1o.

Expression and purification of E1o

was as reported earlier with some modifications [13,91,92]. The E1o component was
purified using a Ni-Sepharose 6 Fast Flow column equilibrated with 20 mM KH2PO4 (pH
7.5) containing 0.20 M KCl, 0.20 mM ThDP, 1.0 mM MgCl2, 1.0 mM benzamidine·HCl
(buffer A) and 30 mM imidazole. After the protein was applied to the column, the
column was washed with 500 mL of 30 mM imidazole and then with 500 mL of 50 mM
imidazole, both in buffer A. The E1o was eluted with 150 mM imidazole in buffer A and
was dialyzed against 2000 mL of 20 mM KH2PO4 (pH 7.5) containing 0.35 mM KCl,
0.20 mM ThDP, 1.0 mM MgCl2, and 1.0 mM benzamidine ·HCl for 15 h at 4 oC. For
E1o storage, buffer was exchanged to 20 mM KH2PO4 (pH 7.5) containing 0.20 M KCl,
0.20 mM ThDP and 1.0 mM MgCl2 by ultrafiltration using a concentrating unit with a
cut-off of 30 kDa. The E1o was stored at -80 oC.
2.5.2.2 Expression and purification of the E2o and its variants. Expression

and

purification of E2o was as reported earlier for human E2p with some modifications
[18,19]. AG1 cells were grown in LB medium supplemented with 35 µg/mL of
chloramphenicol and protein expression was induced by 0.50 mM IPTG for 5 h at 37 oC.
Harvested cells were resuspended in 20 mM KH2PO4 (pH 7.5) containing 0.30 M NaCl, 1
mM benzamidine·HCl, 1 mM DTT, and two protease inhibitor cocktail tablets. The
resulting cell suspension was incubated with lysozyme (0.60 mg/mL) for 20 min on ice.
Next, MgCl2 (5 mM) and 1000 U each of DNase I and Micrococcal Nuclease were
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added, and the cells were incubated for an additional 20 min on ice. Cells were then
disrupted by ultrasonication at a setting of 6 using 10 s pulse ‘on’ and 30 s pulse ‘off ’for
total time of 5 min. PEG-8000 (50% w/v) was added drop-wise to the clarified lysate to
6% (v/v) and the precipitated pellet was dissolved in 20 mM KH2PO4 (pH 7.5) containing
0.30 M NaCl, 1 mM DTT, 1.0 mM benzamidine·HCl and 1 mM EDTA. The E2o was
purified using a Sephacryl S-300 High Resolution size-exclusion column equilibrated
with 20 mM KH2PO4 (pH 7.5) containing 0.30 M NaCl, 1 mM DTT, 1.0 mM
benzamidine·HCl and 1 mM EDTA. Fractions containing E2o according to PAGE were
collected and E2o was precipitated by ultracentrifugation for 4.0 h at 140,000 g. The
pellet was dissolved in 20 mM KH2PO4 (pH 7.5) containing 0.40 M NaCl, 0.50 mM
EDTA, 1,0 mM DTT and 1.0 mM benzamidine·HCl for 15 h at 4 oC. The clarified E2o
was stored at -80 oC.
The E2o variants with Thr323Ala, Thr323Ser, Asp374Ala, Asp374Asn, His375Ala,
His375Cys, His375Asn, Arg376Ala, and Asp379Ala substitutions were created using the
pCA24N-E2o plasmid as a template and two synthetic oligonucleotide primers
complementary to the opposite strands of the DNA with Quik-Change site-directed
mutagenesis kit and Protocol supplied by the manufacturer (Stratagene, La Jolla, CA).
The following oligonucleotide primers and their complements were used (mismatched
bases are underlined, and mutated codons are shown in boldface type):
5’-AACTTCACCATCGCGAACGGTGGTGTGTTCGGTTCC-3’ (Thr323Ala),
5’-AACTTCACCATCAGCAACGGTGGTGTGTTCGGTTCC-3’ (Thr323Ser)
5’-CTGGCGCTGTCCTACGCGCACCGTCTGATC-3’ (Asp374Ala)
5’- GGCGCTGTCCTACAACCACCGTCTG-3’ (Asp374Asn)
5’-GCGCTGTCCTACGATGCGCGTCTGATCGAT-3’ (His375Ala)
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5’-GCGCTGTCCTACGATTGCCGTCTGATCGAT-3’ (His375Cys)
5’-GCTGTCCTACGATAACCGTCTGATCG-3’ (His375Asn)
5’-TCCTACGATCACGCGCTGATCGATGGTCGC-3’ (Arg376Ala)
5’-CACCGTCTGATCGCGGGTCGCGAATCCGTG-3’ (Asp379Ala)
5’-GGCGCTGTCCTACGATNNSCGTCTGATCG-3’ (His375X) where N = A/T/G/C
and S = G/C
The presence of substitutions was verified by DNA sequencing with specific primers at
the Molecular Resource Facility of Rutgers New Jersey Medical School (Appendix B).
2.5.2.3 Expression and purification of LDo and E2o 1-176 didomain.

Expression

and purification of the E2o lipoyl domain (LDo, residues 1-105 in E2o) and E2o1-176
didomain was as reported earlier for E. coli LDp and E2p1-190 [19,93]. The representation
of the individual domains that were used for the experiments are described in Figure 2.7.
To ensure full lipoylation of the LDo and E2o1-176 di-domain, these E2o derived domains
were lipoylated in vitro by an E. coli protein lipoyl ligase as reported earlier [91].
Lipoylation of each E2 derived domain was confirmed by FT-MS (data not shown).

Figure 2.7 E2o Constructs that were used for the experiments. Each of the constructs
were expressed separately, and the recombinant proteins were purified before subsequent
activities were measured.
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2.5.2.4 Expression and purification of the E2o catalytic domain and its His375Ala
and Asp374Ala variants.

For expression of the CDo, DNA encoding residues 93 –

404 corresponding to catalytic domain (Figure 2.7) [16], subunit binding domain and
linker connecting them in wt-E2o was synthesized and was cloned into pD451-SR vector
by DNA 2.0 Inc. (Menlo Park, CA). DNA encoding CDo with His6 tag at the C-terminal
end was introduced into BL21 (DE3) cells (Novagen) and cells were grown in LB
medium supplemented with 35 µg/mL of kanamycin at 37 oC overnight. 15 mL of the
overnight culture was inoculated into 800 mL of the LB medium supplemented with
kanamycin (35 µg/mL) and cells were grown to OD600 of 0.5-0.6 at 37 oC, and then IPTG
(0.5 mM) was added, and cells were grown for an additional 5 h at 37 oC. The cells were
then washed with 50 mM KH2PO4 (pH 7.5) containing 0.15 M NaCl and were stored at 20 oC. The harvested cells were resuspended in 20 mM KH2PO4 (pH 7.5) containing 0.30
M NaCl, 1 mM benzamidine·HCl, 1 mM DTT, and two protease inhibitor cocktail
tablets. Cells were treated with lysozyme (0.6 mg/mL) at 4 oC for 20 min and then with
DNase I (NEB) and Micrococcal Nuclease (NEB) (1,000 units of each) for an additional
20 min at 4 oC. Cells were disrupted by a sonic dismembrator with 10 s pulse “on” and 30
s pulse “off” for 5 min. The supernatant was centrifuged at 30,000 g for 20 min. The
clarified lysate was loaded onto a 10 ml Ni-Sepharose 6 Fast Flow column (GE
Healthcare) pre-equilibrated with 20 mM KH2PO4 (pH 7.5) containing 0.30 M NaCl, 1.0
mM benzamidine·HCl and 10 mM imidazole. The column was first washed with 35 mM
imidazole in the same buffer solution. The CDo was eluted with 150 mM imidazole. The
fractions containing CDo were dialyzed against 2,000 ml of 20 mM KH2PO4, containing
0.45 mM NaCl and 1.0 mM benzamidine·HCl by overnight at 4 oC. The CDo was
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concentrated by ultrafiltration with a 10 kDa MW cut off concentrating unit and was
stored at -80 oC.
For construction of Asp374Ala and His375Ala CDo variants, the pD451-SR
plasmid encoding CDo was used as a template, and the amplification primers 5’GCGCTGTC-CTACGATGCGCGTCTGATCGAT-3’

(for

His375Ala)

and

5’-

CTGGCGCTGTCCTA-CGCGCACCGTCTG ATC-3’ (for Asp374Ala) and their
complements were used for site-directed mutagenesis (the mismatched bases are
underlined and mutated codons are shown in boldface type). The QuikChange sitedirected mutagenesis kit was used for single-site substitution (Figure 2.7) (Stratagene, La
Jolla, CA).
2.5.2.5 Expression and purification of E3. Expression and purification of E3 was
carried out exactly following published protocols by the Jordan group [18].

2.5.3 Enzyme Activity Measurement
Overall OGDHc activity was measured in the reaction assay as reported earlier [13]. For
OGDHc assembly, E1o in 20 mM KH2PO4 (pH 7.0) containing 0.15 M NaCl was
assembled with independently expressed E2o and E3 components with a mass ratio of
E1o:E2o:E3 of 1:1:1 (µg/µg/µg) for 20 min at 25 oC. Reaction was initiated by 2-OG (2
mM), or pyruvate (25 mM), or 2-OV (45 mM), and CoA (0.13 mM).
In the OGDHc assay with CDo and LDo replacing E2o, the E1o (60 µg, 1.4 µM
subunits) in 50 mM KH2PO4 (pH 7.0) was first preincubated with independently
expressed CDo or CDo variants (60 µg, subunits 4.9 µg) and E3 (60 µg, 2.9 µM subunits)
at a mass ratio of 1:1:1 (µg: µg: µg) at 25 oC. An aliquot with 5 µg of E1o (0.11 µM
subunits) was then withdrawn and was mixed with varying concentrations of LDo in a
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cuvette containing all components needed for OGDHc assay. After 1 min of equilibration
at 30 oC, the OGDHc reaction was initiated by the addition of 2-OG (2 mM) and CoA
(0.13 mM) as above.

2.5.4 Site Saturation Mutagenesis in the E2o Core Domain on the His375 Residue
Creation of the mutagenic library.
The site saturation mutagenesis technique was used to create a library at the His375
position in the E2o core domain using a modified procedure for QuikChange Site
directed mutagenesis kit and using NNS primers:
5’-GGCGCTGTCCTACGATNNSCGTCTGATCG-3’ (His375X) where N = A/T/G/C
and S = G/C. The pCA24N-E2o wild-type plasmid DNA was used as template. A typical
50 mL reaction contained 10x PfuUltra buffer, dNTP (0.2 mM) and PfuUltra DNA
polymerase (1U), pCA24N encoding E2o as template, and NNS primers listed above.
The PCR reaction consisted of 16 cycles at 95 °C for 30 s, 55 °C for 1 min and 68 °C for
10 min. After the PCR, DpnI was added to the reaction mixture and then PCR product
was transformed into E. coli BL21 (DE3) competent cells and plated on LB-agar plate
containing 30mg/ml chloramphenicol and was incubated overnight at 37 oC. The
transformants were emulsified and stored as 20% glycerol frozen stocks at -80 oC.
Growth and expression
The library was plated onto an LB-Agar plate containing chloramphenicol antibiotic
(50 µg/ml) to obtain single colonies. Approximately 270 single colonies were picked and
inoculated into a 96-well plate containing LB medium and chloramphenicol (50 µg/ml) to
make master plates. The master plates were incubated at 37 oC at 250 RPM. Next,
duplicate plates were constructed by inoculating (50x dilution) deep well plates that
32

contained 1 ml LB media, chloramphenicol, d,l-lipoic acid (0.3 mM) and IPTG (1 mM)
for E2o. The deep-well plates were incubated at 37 oC at 250 RPM. The cells were
centrifuged at 1600 g and the media was discarded. The cell pellets were stored -20 oC
until use. The cell pellets were resuspended and lysed in a buffer containing KH2PO4 (20
mM), NaCl (0.15 M), DTT (1 mM), protease inhibitor cocktail tablet, lysozyme (1
mg/ml), DNAse (0.1 mg/ml) and incubated for 1 h at 37 oC. The lysate was centrifuged
twice at 1600g for 30 min and the clarified supernatant was used for the subsequent steps.
The E1o and E3 components were over-expressed separately each in 1.6L culture
medium following published protocols and lysed [18]. The lysates of E1o, E2o and E3
were reconstituted in a 96 well plate (total volume 300 µl) buffer containing KH2PO4 (20
mM), NaCl (0.15 M), MgCl2 (1 mM) and ThDP (0.1 mM) in a ratio of 1:2:1 as per
OD600nm/µl for 1 h and mixed well. The first column on the plate was the wild-type
OGDHc complex as shown in the Figure 2.8, represented by the screen section.
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Figure 2.8 Schematic representation of the steps followed for high-throughput screening
assay.
Screen and validation
The overall activity was measured in a 200 µl flat-bottomed 96-well plate containing 0.1
M Tris-HCl (pH 8.0), MgCl2 (1 mM), ThDP (0.1 mM), DTT (2.6 mM), NAD+(2.5 mM),
CoA (0.13 mM) and substrate OG (5-10 mM). NADH production was measured by the
initial rate of reaction at 340 nm.

The reaction was initiated using 60 µl of the

reconstituted complex. The endpoint at 340 nm was measured with a plate reader
(Spectramax ® M2 UV-Vis) after 2, 5, 7 and 10 min.
Those E2 variants were chosen that had similar or higher activity than the wild-type
[(OD 340

final variant x

- OD340

initial variant x)

/ (OD340

final wt

- OD340

candidates were re-screened, and the positive variants were sequenced.
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initial wt)].

The

The rescreening conditions were identical to the screening assay with a minor
modification (Figure 2.8, re-screen). First, identified clones were traced back to the
master plate and re-streaked on an LB-agar plates containing chloramphenicol
(50 µg/ml). The first column was reserved for wild-type and 2 columns or 16 colonies
from a single E2-variant were inoculated into a 96 well plate containing LB medium and
antibiotic. The false positives were discarded (Figure 2.8). The positive clones were
sequenced, overexpressed, and purified following the same protocol for E2o as described
above. Next, the purified E2 variants were reconstituted with purified E1o and E3 and
kinetic parameters were determined.

2.5.5 Fluorescence Spectroscopy
To determine the dissociation constant of CoA and succinyl-CoA with the E2o
His375Trp variant, to the protein (0.24 mg/mL, concentration of active centers of 3.5
μM) in a mixture of 50 mM KH2PO4 and 50 mM Tris (pH 8.0), containing 0.1 M NH4Cl,
1 mM DTT and glycerol (1% v/v) was added CoA (3-570 µM) or succinyl-CoA (5-380
µM), and the fluorescence spectra were recorded after each addition at 25 oC using a
Cary Eclipse spectro-fluorimeter. The excitation wavelength was 295 nm, and the
emission spectra were recorded in the range of 300-450 nm in 3 mL quartz cuvettes. The
Kd values for CoA were calculated using Equation 2.1.
(Fo – Fi) / Fo = (∆Fmax / Fo[CoA]n) / (S0.5n + [CoA]n)

(2.1)

where (Fo – Fi) / Fo is the relative fluorescence quenching following the addition of CoA
or suc-CoA, n is the Hill coefficient, and for n = 1.0, the value of S0.5 is equal to Kd.
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2.5.6 Reductive Succinylation of the LDo by E1o and OG
For this experiment, the LDo (100 µM) was incubated with E1o (0.015 µM) in 35 mM
(NH4)2CO3 (pH 7.5) containing 0.50 mM MgCl2 and 0.1 mM ThDP. The reaction was
started by addition of 2 mM of 2-OG. Aliquots of 10 µL were withdrawn at times of
5-600 s and were diluted into 1 mL of 50% methanol and 0.1% formic acid to stop the
reaction. Samples were analyzed by ESI FT-MS. The fraction of succinylated LDo at
different times was determined by taking a ratio of the relative intensity of the mass of
the succinylated form to the total relative intensity (sum of unsuccinylated and
succinylated LDo). The time dependence of this fraction was plotted, and the data were
fitted to a single exponential (Equation 2.2) using Sigma Plot 10.0. The rate constant was
calculated from the linear fit to the initial rate conditions.
f = fo + f1 x (1-e-kt)

(2.2)

2.5.7 Succinyltransferase Reaction of the CDo and its His375Ala and Asp374Ala
Variants in the Reverse Direction
The following protocol outlines simultaneous detection of succinylated and
unsuccinylated LDo forms when CDo was used as catalyst in the reverse reaction. The
reaction mixture in 300 µL of the 35 mM NH4HCO3 (pH 7.5) contained the following: 40
µM LDo lipoylated in vitro; 0.10 mM TCEP to keep LDo in the reduced form; 0.15 mM
succinyl-CoA, and 0.05 µM CDo. The reaction was started by addition of CDo after 40 s
of equilibration of the reaction assay and was conducted at 30 oC. Aliquots of 20 µL were
withdrawn at times of 5-120 s and were diluted into 1 mL of 50% methanol and 0.1%
formic acid to quench the reaction. Samples were analyzed by ESI FT-MS. The fraction
of succinylated LDo at different times was determined by taking a ratio of the relative
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intensity of the mass corresponding to the succinylated form to the total relative intensity
(sum of intensities for the unsuccinylated and succinylated LDo). The time dependence
of this fraction was plotted, and data were fitted to a single exponential (Equation 2.2)
using Sigma Plot 10.0. The rate constant was calculated from the linear fit to the initial
rate conditions.

2.6 Results and Discussion
2.6.1 Reductive Succinylation of the Lipoyl Domain by E1o and 2-OG is not the
Rate-Limiting Step in the OGDHc Reaction
Reductive succinylation of the lipoyl moiety covalently attached to the lipoyl domain on
E2o is the final step involving ThDP-bound covalent intermediates formed on the first
E1o component of the OGDHc. It is a concomitant oxidation of the 2-OG derived
enamine and reductive acylation of E2o (Figure 2.7, for C-terminally truncated E2o
proteins created by DNA manipulations and employed in these experiments). According
to Figure 2.6, the S8-succinyldihydrolipoyl-E2o is the product of the reductive
succinylation of the lipoyl-E2o by E1o and 2-OG [94]. Next, transfer of the succinyl
group from the thiol ester of S8-succinyldihydrolipoyl-E2o to CoA takes place
exclusively at the E2o core domain active centers (Figure 2.3), so there is no oxidation–
reduction involved in succinyl transfer, rather it represents a conversion of one thiol ester
to another.
Earlier, an appropriate model reaction was developed [91] to study the rate of
reductive acetyl transfer from E. coli pyruvate dehydrogenase (E1p) to the lipoyl domain
of the dihydrolipoyl transacetylase (E2p), which maintains both the chemistry and the
intercomponent communication due to its specific recognition of E1p [95–97]. The
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method developed takes advantage of the ability to detect and quantify LD-E2p and
acetyl-LD-E2p simultaneously in the quenched reaction mixtures using Fourier transform
mass spectrometry (FT-MS). Analogously, the reductive succinylation of LDo by E1o
and OG under steady-state conditions here examined provides an appropriate model
reaction to study the communication between the E1o and E2o components. The LDo
employed in these studies was fully lipoylated in vitro by E. coli lipoyl protein ligase (see
Materials and methods), and lipoylation was con- firmed by FT-MS [91]. Two LDo
forms were identified by FT-MS: an LDo form with mass of 11421.2 Da that correlates
well with the theoretical mass of LDo = 11420.4 Da, and an LDo form with mass of
11435.2 Da that differs from the previous form by 14 Da, possibly due to methylation of
His6-tag as reported in the literature [98]. Both LDo forms could be nearly completely
reductively succinylated by E1o and OG (>90% succinylation) (Figure 2.9a), leading to
an LDo form with mass of 11523.2 Da (increase in mass by 102 Da on succinylation, the
theoretical mass = 11522.4 Da), and LDo form with mass of 11537.2 Da. An average
(based on three experiments) rate constant of 99 s-1 could be calculated from a steadystate experiment for reductive succinylation of LDo (see Fig. 2.9a for a typical
experiment) and was approximately twice as large as the kcat of 48 s-1 determined from
the overall OGDHc activity measurements in Table 2.1. These data indicate that with a
sufficient amount of LDo in the reaction assay, the succinyl transfer from E1o to E2o is
not a rate-limiting step (48 s-1 is kcat for overall activity vs. 99 s-1 for reductive
succinylation). Importantly, the substrate analogues, 2-OA (kglutarylation = 22 s-1), 2-OV
(kbutyrylation = 0.0084 s-1), and pyruvate (kacetylation = 0.048 s-1), could also be used by E1o as
substrates for reductive acylation of LDo; however, their efficiency was lower than that
with 2-OG (see Figures 2.9a for 2-OG and 2.9b for 2-OA). Finally, this model reaction is
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an important control to assure that the acyl group derived from 2-OG on E1o could be
transferred to LDo before acyl-CoA formation in the active centers of E2o and could lead
to determination of the catalytic rate constants for acyl transfer.

Figure 2.9 Time dependence of the reductive acylation of LDo by E1o and 2oxoglutarate or 2-oxoadipate.

a. The reductive succinylation of the LDo by E1o and OG. LDo (100 µM), E1o (0.048 µM active centers),
0.1 mM ThDP, and 0.5 mM MgCl2 in 35 mM NH4HCO3 (pH 7.5) were mixed with 2 mM OG. At time
interval (5- 240 s), aliquots of 10 µL were withdrawn and were quenched into 1 mL of 50% methanol and
0.1% formic acid. Samples were analyzed by FT-MS. b. The reductive glutarylation of the LDo by E1o and
OA. The LDo (100 µM), E1o (0.075 µM active centers), 0.10 mM ThDP and 0.5 mM MgCl2 in 35 mM
NH4HCO3 (pH 7.5) were mixed with 2.5 mM OA. Samples were analyzed by FT-MS. The relative
intensity of the acylated versus total LDo (sum of acylated and unacylated) was plotted versus time. The
trace is a nonlinear regression fit to a single exponential rise to maximum (see Equation 2.3), and the
dashed line represents a linear fit to initial rate conditions. The rate constants were calculated from the
initial slope.
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Table 2.1 Kinetic Parameters of E2o and its Active Center Variants Assembled into
OGDHc
E2o
Variant

OGDHc activity
a

(µmol·min-1·mg1
)

kcat
(s-1)

kcat/Km
(M-1 s-1)

E1o- activity b
(µmol·min-1·mg-1)

Km, 2-OG
(mM)

Km, CoA
(mM)

wt E2o

13.7 ± 2.5
(100%)

48.0

1.07x106

0.35 ± 0.01

0.05 + 0.011

0.0204

Thr323Ala

6.2 ± 0.30
(45%)
5.9 ± 0.50
(43%)
0.28 ± 0.01
(2.1%)
1.33 ± 0.03
(9.7%)

21.7

0.48x106

0.36 ± 0.01

0.095 + 0.03

0.0233

20.7

0.46x106

0.29 ± 0.03

ND

ND

0.98

0.02x106

0.32 ± 0.02

0.077

ND

4.7

0.10x106

0.40 ± 0.07

0.29 ± 0.03
(2.1%)
0.13 ± 0.01
(1.0%)
0.07 ± 0.01
(0.5%)

1.0

0.02x106

0.30 ± 0.01

0.082

ND

0.46

0.01x106

0.33 ± 0.04

0.26

0.006x106

0.44 ±0.01

Thr323Ser
Asp374Ala
Asp374Asn
His375Ala
His375 Cys
His375Asn
His375Trp*

8.137 + 0.4

28.8

0.52 x106

0.33 ± 0.04

0.07 + 0.02

0.0133

His375Gly*

(59.4%)
1.76 + 0.15
(12.6%)

5.76

0.18 x106

0.37 + 0.08

0.04 + 0.006

0.0206

27.0

0.60x106

0.31 ± 0.04

0.14 + 0.007

0.0198

4.6

0.10x106

0.29 ± 0.01

ND

0.0211

Arg376Ala
Asp379Ala

7.7 ± 0.08
(56%)
1.3 ± 0.07
(9.5 %)

OGDHc was assembled from E1o, indicated E2o variants and E3 at a mass ratio of 1:1:1 (µg: µg: µg).
Activity was calculated per mg of E1o. No OGDHc activity was detected for E1o or E3 in the absence of
E2o.
b)
E1o-specific activity of the assembled OGDH complexes was measured in a DCPIP assay and was
calculated per mg of E1o1. All assays were carried out in triplicates. The E2o* variants are the mutants
picked on site-saturation mutagenesis.
a)
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2.6.2 Residues Asp374 and His375 are the key E2o active site residues
Next, the residue-specific contribution to catalysis of succinyl-CoA formation in the
active center of the E. coli E2o was studied. Results of this study would be applicable to
all E2o components due to high sequence identities reported for all E2o core/catalytic
domains [16,17,19,70,87,88,99]. Putative residues from the active center of the E2o
involved in succinyl transfer and substrate binding were identified based on the X-ray
structure of the truncated cubic core of the E. coli E2o, known as the E2o catalytic
domain (Figure 2.3a) [16,17]. The following E2o active center variants were created to
determine their individual contributions toward the catalytic efficiency of the OGDHc
complexes assembled from E1o, E2o (or its active center variants) and E3: Thr323Ala,
Thr323Ser, Asp374Ala, Asp374Asn, His375Ala, His375Cys, His375Asn, Arg376Ala
and Asp379Ala (Figure 2.3b, Table 2.1). The activity of the assembled OGDHc variants
was measured in the overall assay for NADH production and in an E1-specific assay to
study 2-OG oxidation by OGDHc in the presence of the artificial electron acceptor 2,6dichlorophenolindophenol (DCPIP). The E1-specific activity does not need the presence
of the E2o and E3 components; however, substitutions in E2o could potentially affect
assembly into OGDHc.
As shown in Table 2.1, the Thr323 E2o substitutions to Ala or Ser do not
significantly affect the NADH production as 45% (Thr323Ala E2o) and 43% (Thr323Ser
E2o) of E2o activities were detected. From these results, it is unlikely that Thr323 in E2o
is a catalytically important residue, contrary to the suggestion made based on the X-ray
studies [16]. Similarly, the Arg376Ala E2o substitution led to 56% OGDHc activity
remaining. In contrast, the Asp374Ala and Asp374Asn E2o substitutions revealed 2.1%
and 9.7% of OGDHc activity remaining, respectively. Approximately, 9.5% of the
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OGDHc remaining activity was detected for Asp379Ala substituted E2o (Table 2.1). The
His375Ala, His375Cys and His375Asn E2o substitutions at the highly conserved
histidine residue in all 2-oxo acid dehydrogenase complexes, led to 2.1%, 1.0% and 0.5%
activity remaining, respectively, but did not abolish the OGDHc activity.
These findings are in in agreement with data reported from Rutgers earlier for
amino acid substitutions in His339 for E. coli pyruvate dehydrogenase complex (PDHc)
which is analogues to His375 in E2o [100]. The activity of the E. coli PDHc was reduced
to approximately 5.6% with the His399Ala and 2.8% with the His399Cys substitution,
clearly indicating that cysteine substitution led to a lower activity of both E2’s as
compared with the Ala substitution [100]. When OGDH complexes assembled with E2o
and its variants were tested with pyruvate (25 mM) or 2-OV (45 mM) as potential
substrates for chemo-enzymatic synthesis of acyl-CoA analogues, no NADH production
was detected, indicating that neither acetyl-CoA nor butyryl-CoA could be produced
(data not presented). It is also noteworthy that neither the E1o-specific activity of the
reconstituted OGDH complexes, nor indeed the complex assembly itself, was affected by
the indicated E2o substitutions (Table 2.1).
The following could be concluded: two residues, Asp374 and His375 from the E2o
active center are catalytically important, as substitution of either residue for Ala impaired
E2o catalytic efficiency by 54-fold, while a 107-fold reduction was observed for the
His375Cys E2o variant. Compared to the wild type E2o, the His375Asn substitution
lowered the catalytic efficiency by 178-fold, while the Asp374Asn E2o substitution
lowered it by only 11-fold. The rate retardation resulting from Ala substitution of all five
active center residues here tested is ~125,000 fold [this number represents the product of
(kcat/Km)wild

type

/ (kcat/Km)variant] for each Ala substituted variant. This number could be
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compared to the 30,000-fold rate acceleration for acyl transfer between two aliphatic
thiols reported by Hupe and Jencks in model systems [101].

2.6.3 Functional importance of Asp374 and His375 in independently expressed E2o
catalytic domain
An alternative approach to study coupling of the E2o active center with the peripheral
E1o and E3 components was developed by the Jordan group recently [19]. It employs
independently expressed E2o catalytic domain (CDo) in combination with a lipoyl
domain source originated from E2o, such as lipoyl domain by itself (LDo) or Cterminally truncated E2o proteins, such as E2o1-176 didomain, which consists of LDo, an
E1o and E3 binding domain (peripheral subunit binding domain, PSBD) and flexible
linkers connected them (see Figure 2.7). For this approach, first, the functional
competence of the independently expressed CDo in the overall OGDHc reaction needed
to be proved. As shown in Figures 2.10 and 2.11, on mixing of the CDo with varying
concentrations of the LDo (0-70 µM) (Figure 2.10a), or of E2o1-176 didomain (0 –16 µM)
(Figure 2.11), with E1o and E3 components to complete the OGDH-like complex,
production of NADH could be detected. While the rate of NADH production was
proportional to the concentration of the lipoyl domain source, no evident saturation could
be reached with either LDo or E2o1-176 didomain. Nor could saturation be reached with
the Asp374Ala and His375Ala CD variants (Figure. 2.10b, 2.10c). In the absence of
saturation apparent in Figures 2.10 and 2.11, the values of the second order rate constants
kcat/Km could be calculated from the initial slope for NADH production: 0.124 x 106 M-1
s-1 (CDo+LDo domains); 0.192 x 106 M-1s-1(CDo + E2o1-176 di-domain); 0.028 x 106 M-1
s-1 (CDoAsp374Ala + LDo) and 0.019 x 106 M-1 s-1 (CDoHis375Ala +LDo) in comparison with
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1.07x106 M-1 s-1 for

E2o by itself (Table 2.2). Again, the catalytic efficiency of

Asp374Ala and His375Ala CDo variants was 4.4- and 6.5- fold, respectively, lower than
that for unsubstituted CDo. These results confirm the contribution of Asp374 and His375
to E2o catalysis. Another important conclusion from this study is that the reaction
intermediates could be transferred between active centers of E1o, CDo and E3 in the
presence of lipoyl domain source in the reaction assay with no covalent bond linking
CDo and lipoyl domain source. This is the second example from Rutgers, as similar
findings were reported earlier for the E. coli E2p [19]. In support of these striking
conclusions, the following controls were performed: (i) No OGDHc activity was detected
for LDo on its own in the absence of CDo; (ii) Negligible or no OGDHc activity could be
detected for a mixture of E1o, E3 and CDo, but in the absence of LDo, thereby excluding
any contamination from intrinsic wild-type OGDHc. The results indicate that it will be
sufficient to use independently expressed E2o domains for future active center
engineering of E2o.
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Figure 2.10 Dependence of the OGDHc Activity on Concentration of the Lipoyl Domain
in the Overall Assay with CDo and LDo replacing E2o.

a. The E1o (3 µg, 0.028 µΜ subunits), E3 (3 µg, 0.06 µΜ subunits) and CDo (3 µg, 0.1 µΜ subunits) were
mixed at a mass ratio of 1:1:1 (µg:µg:µg) in 0.1 M Tris-HCl (pH 8.0) containing MgCl2 (1.0 mM), ThDP
(0.2 mM), NAD+ (2.5 mM) and different concentrations of the LDo (0-67.5 µΜ) at 30 oC. After 5 min of
equilibration, the reaction was initiated by OG (2 mM) and CoA (0.13 mM) and NADH production was
recorded at 30 oC for 5 min. b. The Asp374Ala CDo and LDo were used to replace E2o. c. The His375Ala
CDo and LDo were used to replace E2o. Condition of experiment for b and c were similar to that presented
above for a.
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Figure 2.11 Dependence of the OGDHc activity on concentration of the E2o1-176
Didomain in the Overall Assay with CDo and E2o1-176 Didomain replacing E2o.
For experimental conditions, see figure legend to Figure 2.10.

Table 2.2 The Second Order Rate Constants for NADH production in the Overall Assay
where E2o was substituted by its indicated Catalytic Domain Variants and Lipoyl
Domain in comparison with E2o
E2o source

kcat/Km
(M-1 s-1)a
forward direction

E2oa

1.07x106

n/a

CDo+LDo

0.124x106

19.9

CDoAsp374Ala +LDo

0.028x106

1.86

CDoHis375Ala +LDo

0.019x106

4.9

kcat
(s-1)b
reverse direction

Activity was measured in the NADH assay in the physiological direction. bActivity was measured in the
reverse direction. The concentrations of dihydro-LDo were: 35 µM for Asp374Ala CDo and 40 µM for
both His375Ala CDo and for wild-type CDo. For details on activity measurement see Materials and
Methods section.
a
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2.6.4 Further evidence for the catalytic importance of Asp374 and His375 from the
rate of succinyl transfer catalyzed by the E2o catalytic domain
To further substantiate the role of the His375Ala and Asp374Ala substitutions in the
catalytic domain of E2o, an experiment was designed to study the succinyl transfer per se
in the reverse reaction as shown in Equation 2.3, enabling us to determine rate constants
for the reaction taking place in the E2o active center exclusively. A mixture of dihydroLDo [LDo reduced by tris(2-carboxyethyl)phosphine, TCEP] and CDo or its variants,
was reacted with succinyl-CoA according to Equation 2.3 where CDo or variants are the
catalysts for the reaction.
CDo
succinyl-CoA + dihydro-LDo  succinyldihydro-LDo + CoA

(2.3)

Direct measurement of the masses of dihydro-LDo and succinyldihydro-LDo by
FT-MS was used to quantify the rate of succinyl transfer from succinyl-CoA to the
dihydro-LDo. At concentrations of dihydro-LDo (40 µM), succinyl-CoA (0.15 mM), and
CDo (0.05 µM), the dihydro-LDo is a substrate, CDo is a catalyst, and succinyldihydroLDo is a product in Equation 2.3. The reaction was stopped at different times (5–120 s)
by diluting into 50% methanol and 0.1% formic acid, and the samples were analyzed by
FT-MS. The ratio of succinyldihydro-LDo / total LDo (the sum of succinyldihydro-LDo
and dihydro-LDo) was plotted versus time (Figure 2.12a). As seen from Figure 2.12a,
approximately 60% of dihydro-LDo is converted to succinyldihydro-LDo with a rate
constant of 19.9 s-1 as calculated from a linear fit to the initial rate of succinyldihydroLDo formation (Table 3). It should be noted that some time-dependent formation of
succinyldihydro-LDo was detected by FT- MS even in the absence of CDo in the reaction
assay. While this nonenzymatic reaction was insignificant with unsubstituted CDo, the
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slope of this nonenzymatic reaction was taken into account when rate constants were
calculated for the His375Ala and Asp374Ala CDo variants (Figure 2.12 b,c). As seen in
Figure 2.12 and Table 2.2, the rate constant of 1.86 s-1 (Asp374Ala) and of 4.9 s-1
(His375Ala) was 11 times and 4 times smaller, respec- tively, compared to the rate
constant of 19.9 s-1 for unsubstituted CDo. A ratio of succinyldihydro-LDo/total LDo of
~ 0.55–0.60 (reproducible with wild-type and variant CDo’s in Fig. 6) was observed. The
data above, and presented in Table 2.2, support the conclusion that Asp374 and His375
are important residues for succinyl transfer in both directions, as they need to be, while
also suggesting an equilibrium constant near unity for the reaction in Equation 2.3.
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Figure 2.12 Kinetics of Succinyldihydro-LDo formation by CDo and variants in the
Reverse Succinylltransferase Reaction.

a. The dihydro-LDo (40 µM), 0.10 mM TCEP and 0.05 µM CDo in 35 mM NH4HCO3 (pH 7.5) were
mixed with 0.15 mM succinyl-CoA. The reaction was stopped by addition of 50% methanol and 0.1%
formic acid and samples were analyzed for the presence of succinyldihydro-LDo and dihydro-LDo by FTMS. The relative intensity of succinyldihydro-LDo versus total intensity (sum of succinyldihydro- and
dihydro-LDo) was plotted versus time. A control experiment was performed in the absence of CDo. b.
Progress curves of succinyldihydro-LDo formation by Asp374Ala CDo. The reaction assay in 0.30 ml of
35 mM NH4HCO3 (pH 7.5) contained the following: 35 µM dihydrolipoyl-LDo, 0.35 mM TCEP and 0.15
mM succinyl-CoA. After 40 s of pre-incubation, the reaction was started by addition of 0.10 µM
Asp374Ala CDo. c. Progress curves of succinyldihydro-LDo formation by His375Ala CDo. The reaction
assay was similar to that in b except of 40 µM dihydrolipoyl-LDo was used. The traces are the nonlinear
regression fit to a single exponential rise to maximum, and the dashed line represents a linear fit to initial
rate conditions. For rate constants calculation in b and c, the slope in the control experiment was subtracted
from that in the experiment.
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2.6.5 Site saturation mutagenesis on the E2o active center His375
To gain further insight into the possible role of His375, out site-saturation mutagenesis
was carried out on this residue and screened for possible variants that display OGDHc
activity.
The following His375 variants were identified: His375Trp E2o with a significant
retention of the overall NADH activity (60%); and His375Gly E2o with significantly
reduced NADH activity (13%) compared to unsubstituted E2o (Table 2.1). Steady-state
kinetic experiments revealed an approximately twofold reduction in kcat for the
His375Trp E2o (29 s-1) and about eightfold reduction for the His375Gly E2o (6 s-1)
compared to E2o (48 s-1) (Table 2.1; Figures 2.13 a,b,c). No significant changes in
values of Km with respect to 2-OG or CoA were detected for the variants in comparison to
the unsubstituted E2o (Table 2.1, Figure 2.14a). To further test whether His375
participated as a general acid–base catalyst, the pH dependence of the overall NADH
activity of the His375Trp E2o and of the unsubstituted E2o, both assembled with the E1o
and E3 components, was com- pared and revealed no difference in their shapes. The
pKapp for the alkaline limb of the curve was 8.8 for E2o and 8.7 for the E2o-His375Trp
variant (Figure 2.14b). This parallel behavior of the pH dependence with His or Trp
effectively rules out an acid–base role for His375.
As there is no tryptophan residue in the E2o active center, the intrinsic fluorescence
could be utilized of the newly installed Trp in position 375 of the His375Trp E2o variant
to determine the nearly equal Kd of CoA (61.2 µM) and succinyl-CoA (47 µM) from
quenching of fluorescence on addition of either compound (Figure 2.15). As control, the
E2o experienced no fluorescence quenching, thus also confirming substitution at the
active center. In view of the modest decrease in kcat/Km with the Trp substitution at
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position 375, these Kd values are appropriate for the unsubstituted E2o, and indicate
similar binding affinity of E2o for CoA and succinyl-CoA, where both succinyl and CoA
moieties appear to contribute to binding.

a

b

c

Figure 2.13 Dependence of the NADH production in the OGDHc reaction on
concentration of the 2-oxoglutarate substrate for the (a) wild type complex, (b) E2 mutant
His375Trp and (c) His375Gly.
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a

b

Figure 2.14 (a) Dependence of the NADH production in the OGDHc reaction on
concentration of the Coenzyme A.
NADH assay with wild type E2o, E2His375Trp and E2His375Gly.

(b) pH dependence of the OGDHc activity for wild-type E2o and His375Trp E2o variant.

The E1o (3 µg, 0.028 µΜ subunits), E3 (3 µg, 0.06 µΜ subunits), and wild-type E2o (3 µg, 0.1 µΜ
subunits) or His375Trp E2o were mixed at a mass ratio of 1 : 1 : 1 (µg: µg: µg) in the reaction assay
containing 0.05 M Tris/HCl, 0.05 M KH2PO4, MgCl2 (1.0 mM), ThDP (0.2 mM), and NAD+ (2.5 mM)
with pH of the reaction assay varied from 6.28 to 8.5. The reaction was initiated by CoA (0.13 mM) and
OG (2 mM) and NADH production was recorded at 30 °C for 1 min. The values of activity were plotted to
a curve defined by one ionizing group according to Equation (2.4).
log(activity)= log(activitymax) - log (1+10pK1-x)
(2.4)
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Figure 2.15 Quenching of the intrinsic fluorescence of the His375Trp E2o by CoA and
succinyl-CoA.

a. The top panel shows the dependence of the relative fluorescence quenching on the concentration of CoA.
His375Trp E2o (0.24 mg/mL, concentration of active centers of 3.5 μM) in a mixture of 50 mM KH2PO4
and 50 mM Tris (pH 8.0) containing 0.15 M NH4Cl, 1 mM DTT and 1% glycerol was titrated with CoA
(3−570 μM). b. The bottom panel shows the dependence of the relative fluorescence quenching on the
concentration of succinyl-CoA (5−380 μM). Data points in a and b were fit to Hill Equation (2.1); the lines
are the regression fit trace.

2.7 Conclusions
This chapter is directed to an elucidation of the fundamental mechanism of the
transthioesterification reaction carried out by the E2o of the E. coli OGDHc that would
be applicable to all E2o components due to high sequence identities reported for the E2
catalytic domains [16,17,19,70,87,88,99]. Important classes of enzymes carrying out
similar reactions include inteins in expressed protein ligation [102] and many reactions
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on the polyketide pathways [103]. Based on the studies, the following important results
emerged.
(a) Identification of catalytically important Asp374 and His375 residues of the E2o
catalytic domain and the rate acceleration provided by these residues. The other residues
tested displayed much smaller contribution to catalysis. Using the E2o variants
substituted by alanine at the putative catalytic center for transthioesterification, NADH
production as a measure of the complex activity indicated that the five residues tested
accounted for 2.23 (Thr323Ala), 54 (Asp374Ala and His375Ala each), 1.78
(Arg376Ala), and 11 (Asp379Ala)-fold rate accelerations for a total of ~125,000-fold.
This is the first identification of partial catalytic rate constants for this important reaction
and raises the question: Which likely mechanism is consistent with the results?
(b) A closer look at the transthioesterification mechanism was provided by the use of
independently expressed E2o domains (LDo, E2o1–176, and CD) that allowed to the
conclusion that both Asp374 and His375 are important residues for succinyl transfer in
both the physiological and in the reverse direction.
(c) The rate of reductive acylation of LDo by a number of substrate analogues (2oxoadipate, 2-oxovalerate and pyruvate) signals that communication between E1o and
E2o is not fatally compromised by the alternative substrates. The rate constant of 99 s-1
for reductive succinylation of the LDo by E1o and 2-OG (the rate constant for the
reaction starting with free enzyme and culminating in reductive succinylation of E2o,
resulting in formation of S8-succinyldihydrolipoyl-LDo) compared to the kcat of 48 s-1
(NADH formation by OGDHc).
(d) These results raise the question: Which likely mechanism of transthiolacylation is
consistent with the experimental findings? Based on numerous precedents, there are two
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prominent likely mechanisms to account for the transfer of acyl group between two thiols
depicted by the step characterized by the rate constants k6 and k-6 in Figure. 2.6. A
general acid–base mechanism would suggest that the His375 converts the thiol of the
attacking nucleophile (CoA-SH) to a thiolate anion (CoAS-) as depicted on pathway B in
Figure 2.16. The activated thiolate then attacks the carbonyl atom of the
succinyldihydrolipoyl-E2 to form a tetrahedral intermediate, which is stabilized by the
hydroxyl side chain of Thr323 [17]. This notion was long accepted based on analogy with
a mechanism developed for chloramphenicol acetyltransferase (CAT) [69,71,75]. When
the analogous His195 in chloramphenicol acetyltransferase was replaced by Ala, a 9x105fold decrease in kcat and virtually no change in Km was observed, that is, a (kcat / Km)wildtype CAT/(

Km)

kcat / Km)His195Ala CAT = 500 000 [19]. In contrast, the (kcat / Km) unsubstituted E2o/ (kcat /

His375Ala E2o

= 54. This difference strongly suggests different functions for the highly

conserved active center histidine on the two enzymes.

Figure 2.16 Likely mechanisms of succinyl transfer from dihydrolipoamide-E2o
to CoA-SH.

Pathway A: direct attack by the conjugate base thiolate anion of CoASH assuming a low pKa for the
CoASH, or by the thiol form itself. Pathway B: initial proton transfer from CoASH to His375 forming the
conjugate base CoAS-, which is the attacking agent. Both pathways then proceed by an oxyanionic
tetrahedral intermediate consistent with model studies [101].
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As a ‘gold standard’ for acid–base catalysis by a histidine side chain, comparison
with the much studied His64 at the catalytic triad of the subtilisin family of serine
proteases, where the His64Ala substitution led to a reduction of 106-fold in kcat/Km, a
number similar to that observed for CAT [104] is also presented.
As an alternative to acid–base catalysis, for a protein with a pKa for the cysteine
thiol group near pH 7.0, one could envision direct attack by a thiolate anion on the thiol
ester carbon, forming an essentially symmetrical tetrahedral oxyanionic intermediate, in
which the central carbon atom is flanked by two C–S bonds, where either C–S bond has
nearly equal probability for cleavage (Figure 2.6, lower left and Figure 2.16 pathway A)
[101]. It can be suggested that the nearly equal magnitude of the rate acceleration
provided by the His375 and the Asp374 residues, more likely, reflects their roles in
stabilizing the oxyanion by two hydrogen bonds (Figure 2.16, pathway A), in other words
creating a so-called ‘oxyanion hole’.
It had been demonstrated some years ago that in subtilisin, where a putative
transition state stabilizing oxyanion hole is created by one main chain hydrogen bond
donor and one side chain hydrogen bond donor (Asn155), substitution of Asn155 to Leu
had small effect on the Km but reduced the kcat by a factor quoted as 200- to 300-fold
[105]. This is very similar in magnitude to the kcat/Km reductions observed (54 for each)
with the Asp374Ala and His375Ala substitutions reported in this study (again no change
in Km was observed).

These results also concur with homology modelling studies

between the enzymes chloramphenicol acetyl transferase and dihydrolipoamide acetyl
transferase about existence of a His-Asp-Gly consensus in the catalytic core which is
likely to play an important role [71].
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While well accepted, it has been difficult to obtain experimental proof for the
existence of an oxyanion in solution; as an example, proton inventory solvent kinetic
isotope effect studies, a very subtle method, failed to do so [106].
The proposed hydrogen bond donation by Asp374 and His375 was tested by
studying the alternative Asp374Asn substitution in E2o that allows hydrogen bond
donation similar to His375 (Table 2.1). The His375Asn substitution led to 4.0-fold
further reduction in the E2o catalytic efficiency (to 0.5% of the remaining activity)
compared to the His375Ala substitution (to 2.1%). In contrast, the Asp374Asn
substitution partially rescued the E2o catalytic efficiency (9.7%) compared to Asp374Ala
E2o (2.1% activity) and suggested that Asp374 is more likely to be involved in hydrogen
bond formation. The result also raises an important implication that the carboxyl group of
Asp374 has an unusually elevated pKa as only in the conjugate acid form could it serve as
a hydrogen bond donor. As this step appears to be part of rate limitation, it can be further
speculated that the alkaline limb of the two activity–pH profiles (parallel for His375 or
Trp375), and the deduced pKa of 8.7–8.8 pertains to a highly perturbed Asp374
environment.
The His375 residue appears to be more sensitive to substitutions, suggesting a more
complicated scenario. Therefore site-saturation mutagenesis was carried out on this
residue and screened for substitution-tolerant active variants. Informatively, the
His375Trp and His375Gly variants were found to have intermediate activity (60% and
13%, respectively). Steady-state kinetic analysis of the enzymes harbouring these
substitutions revealed only modest changes in Km. But, the two-fold decrease in the kcat
for E2o-His375Trp compared to the wild-type E2o is inconsistent with the earlier
suggestion that His375 acts as a proton donor for protonation of the leaving group. These
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results are consistent with studies by McLeish’s laboratory on the ThDP-dependent
enzyme benzoylformate decarboxylase, where similar changes were observed on sitesaturation mutagenesis studies based on the active site His281, by finding that the
His281Phe and His281Trp variants displayed significant activity [107], and also arguing
strongly against acid–base catalytic activity. Additional argument against an acid–base
role of His375 is provided by the similar activity–pH profiles of unsubstituted E2o and its
His375Trp variant.
Given the results with the E2o- His375Trp variant, assigning a role to the His375
side chain need to be done cautiously: rather than a direct participation in a hydrogen
bond as suggested in Figure 2.16, perhaps the imidazole ring provides a physical barrier
protecting the hydrogen bonding unit, a role that could also be played by the indole side
chain of Trp. Of course, there is also the possibility that the indole NH of Trp375 is the
hydrogen bond donor for oxyanion stabilization.
Using a variety of experiments, the accumulated evidence allowed the conclusion
that the rate-limiting step on OGDHc is succinyl transfer to CoA in the E2o active center.
In contrast, on the E. coli PDHc, the rate-limiting step is the initial addition of substrate
to the E1p component forming the first covalent pre-decarboxylation intermediate [26].
The results also provide crucial information for further engineering of the E2o component
for producing a variety of acyl-CoA analogues.
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CHAPTER 3
ENGINEERING 2-OXOGLUTARATE DEHYDROGENASE TO A 2-OXO
ALIPHATIC DEHYDROGENASE COMPLEX BY OPTIMIZING
CONSECUTIVE COMPONENTS
3.1 Introduction
Multienzyme complexes are attractive for one-pot sequential step chemical synthesis of
complex molecules. Enzymes catalyze reactions with high yield and enantioselectivity
under mild conditions [108–112], which makes them desirable for fine chemical,
pharmaceutical, and agricultural industries [59,113]. Next, they facilitate the formation
enzyme-substrate complex for improved catalytic efficiency. For example, the substrate
is channeled from one catalytic center to the next one. This prevents intermediates from
diffusing into the cytoplasm. Furthermore, cellular damage is avoided, which may be
caused from toxic byproducts [114,115].
Multienzyme complexes are found in conserved metabolic pathways across all
kingdoms [116]. It is believed that their primitive ancestors were once promiscuous. They
performed a multitude of bond forming/breaking reactions with a variety of mechanisms
[116,117]. Hence, a relatively small set of enzymes supported numerous pathways to
sustain life. As time marched forward, gene duplication and divergence led to enzymes
with exquisite catalytic efficiency in particular metabolic pathways [118]. Therefore,
metabolic pathways have been reprogrammed for survival of the organism. This
necessitates conversion of a specialist for a particular substrate to a generalist with broad
substrate specificity, then back to a specialist with a new function.

Optimizing a

multienzyme complex requires engineering the component for each individual reaction,
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which may include two or more proteins. This can be achieved via laboratory or directed
evolution, which have become the method of choice for protein design [44,119–122].
The Escherichia coli 2-oxoglutarate dehydrogenase (OGDHc) multienzyme
complex was converted into a 2-oxoaliphatic acid dehydrogenase with broader substrate
specificity. The natural substrate for OGDHc is 2-oxoglutarate (2-OG) and the enzyme
was engineered to accept 2-oxovalerate (2-OV) (Figure 3.1).

Figure 3.1 Substrate structures.

The OGDHc catalyzes a rate-limiting step in the Krebs cycle and it belongs to the
super-family of 2-oxo acid dehydrogenase complexes [3,12].

The Krebs cycle

commences with condensation of oxaloacetate with acetyl-Coenzyme A, the latter being
a product of the pyruvate dehydrogenase member of the super-family, while pyruvate is
the end product of glycolysis. OGDHc is composed of three components: (1) the thiamin
diphosphate (ThDP)-dependent 2-oxoglutarate dehydrogenase/decarboxylase (E1o, EC
1.2.4.2, 105 kDa/subunit), (2) dihydrolipoylsuccinyl transferase (E2o, EC 2.3.1.6, 45
kDa/subunit), and (3) dihydrolipoyl dehydrogenase (E3, EC 1.8.1.4, 55 kDa/subunit). In
E. coli, E1o and E3 exist as homodimers. The E2o component is a trimeric multidomain
protein, starting with the amino terminal end a flexible lipoyl domain (LDo), followed by
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a long mostly unstructured subunit binding domain for assembly with E1o/E3, then a
central nexus catalytic core domain (CDo). The proposed complex contains 12 E1o: 24
E2o :12 E3 (total mass of 2.5 MDa) [6,7]. The OGDHc has three substrate specificity
checkpoints: one is in E1o and other two in E2o (CDo and LDo)[13]. The overall
reaction of OGDHc proceeds according to Equation 3.1. While the detailed reactions
proceed by a succession of reactions (Equations 3.2-3.5).

2-OG + CoASH + NAD+succinyl-CoA + CO2 + NADH + H+

(3.1)

RC(=O)COOH + E1o-ThDP  CO2 + E1o-ThDP=C(OH)R (an enamine)

(3.2)

E1o-ThDP=C(OH)R + lip(S-S)-E2o  E1o-ThDP + RC(=O)S-lip(SH)-E2o

(3.3)

RC(=O)S-lip(SH)-E2o + HS-CoA  R(C=O)-S-CoA + lip(SH)2-E2o

(3.4)

lip(SH)2-E2o + E3-FAD + NAD+  lip(S-S)-E2o + NADH + H+ + E3-FAD

(3.5)

[R = -(CH2)2-COOH, ThDP = thiamin diphosphate, lip(S-S) = oxidized lipoate on E2o,
lip(SH)2 = reduced lipoate]
The OGDHc controls the carbon flux through the Krebs cycle [2].

OGDHc

catalyzes formation of CoA linked thioesters via trans-thioesterification, which makes it a
suitable candidate for green chemical synthesis. Thioesterification reactions are of
importance in both organic chemistry and chemical biology[123,124]. For example, they
are found in antibiotics and natural products [36,125]. Thioester derivatives are also
useful for the synthesis of heterocyclic compounds and molecules containing carbonyl
functional groups[126–128]. Hence, thioester synthesis is essential in the industrial, and
pharmaceutical industries. Traditional thioester synthesis requires an acyl source
available from carboxylic acids, acid anhydrides, or acid chlorides. The reaction
conditions are harsh and energy intensive, often requiring strong bases, long reflux
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conditions, and toxic heavy metals[41]. Thus, recombinant engineered OGDHc may be
provide a green alternative method to chemical synthesis of acyl-CoenzymeA thiolesters.
The Escherichia coli OGDHc was converted into a 2-oxoaliphatic acid
dehydrogenase. The natural substrate for OGDHc is 2-OG. The E1o and E2o of the
complex were engineered to accept 2-oxovalerate (2-OV) (Figure 3.1). The E1o
His298Asp variant was identified from saturation mutagenesis libraries to be active
towards 2-OV. The catalytic efficiency of E1o His298Asp variant increased 4.4-fold for
2-OV, while a 1200-fold decrease for 2-OG resulted in the E1o-specific assay (assay with
DCPIP, 2,6-dichlorophenolindophenol)[13]. However, when the E1o-His298Asp was
reconstituted with wt-E2o and E3, it did not display overall activity (NADH production)
with 2-OV. Mass spectrometric evidence showed that wild-type and E1-His298Asp
transfers the ThDP-bound decarboxylated intermediate of 2-OG or 2-OV to the E2o
lipoyl domain (Equation 3.2). However, the lack of overall activity for 2-OV indicated
that butyryl-coenzyme A was not formed in the E2o-CD. Hence, the reaction was halted
in the E2o-LDo at the S8-butyryldihyrdolipoyl-E2o intermediate. It became evident that
the E2o-CD active center required engineering to complete the reaction. The X-ray
structure of the E. coli E2o-CD indicated that the residues Ser330, Ser333 and His348
may interact with the succinyl carboxylate of the LDo substrate intermediate[16,17]
(Figures 3.2a, 3.2b). The side chains of Ser330, Ser333, and His348 were proposed to
form a hydrogen bond with the terminal carboxylate of the 2-OG.

Amino acid

substitutions at these positions may result in accepting a hydrophobic substrate (Figure
3.2b). Hence, these amino acids were targeted for saturation mutagenesis. The libraries
were screened for overall activity with 2-OV and E2o-Ser333Met, E2o His348Phe, E2o
His348Gln and E2o His348Tyr were identified to be active towards 2-OV. In addition,
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the variant complexes could also accept a larger and more hydrophobic substrate, 2-oxo5-hexenoic acid (2-OHe) (Figure 3.1).

Figure 3.2 E2oCD structure and active site. (a) The E2o-core depicted as a trimer with
the surface area shown.

The ribbons of three colors cyan, red and green represents chains a, b and c respectively (PDB id: 1c4t).

(b) The active-site binding pocket of the E2oCD trimer is represented. Ser330, Ser333
and His348 are shown to be lining the active site.

S8-succinyl dihydrolipoamide (ligand) was docked into the active site pocket of the E2oCD (receptor). The
docking calculations were performed with AutoDock Vina v.1.1.2 using Chimera to visualize [129,130].
The terminal carboxylate oxygen of S8- succinyl dihydrolipoamide is at a distance of 3.2 Å from the
His348 imidazole-N(3) and 2.7 Å from the Ser333 sidechain-OH.

3.2 Materials and Methods
3.2.1 Reagents
Dithiothreitol (DTT), 2-oxoglutarate (2-OG), 2-oxovalerate (2-OV), butyryl-CoA were
from Sigma Aldrich (St. Louis, Mo). NADH, CoA, isopropyl-β-D-thiogalactopyranoside
(IPTG), DNase I, Micrococcal Nuclease, DL-α-lipoic acid and ThDP were from
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Affymetrix (Cleveland, OH). Protease inhibitor cocktail tablets were from Roche
Diagnostics GmbH (Germany). Ni Sepharose 6 Fast Flow and HiPrepTM 26/60
SephacrylTM S-300 HR column were from GE Healthcare (Pittsburgh, PA). QuikChange
Site-Directed Mutagenesis Kit was from Agilent Technologies (Santa Clara, CA).
Primers for site-saturation mutagenesis were from Fisher Scientific (Pittsburgh, PA). E.
coli strain JW0715 containing the pCA24N plasmid encoding the E1o component and
JW0716 containing pCA24N plasmid encoding the E2o component were obtained from
National Bio Resource Project (NIG, Japan). AG1 cells (Agilent Technologies) were
used as host cells. DNA sequencing was carried out by Molecular Resource Facility at
New Jersey Medical School, Rutgers University.

3.2.2 Creation of the saturation mutagenesis library and screen
Site-directed saturation mutagenesis libraries for E2o at positions Ser330, Ser333 and
His348 were constructed using a modified QuikChange procedure, very similar as
described in Chapter 2. A typical 50 µL reaction contained 10x PfuUltra buffer, dNTP
(0.2 mM) and PfuUltra DNA polymerase (1U), pCA24N encoding E2o as template, and
NNS primers listed as in Table 3.1. The PCR reaction consisted of 16 cycles at 95 °C for
30 s, 55 °C for 1 min and 68 °C for 10 min. After the PCR, DpnI was added to the
reaction mixture and then PCR product was transformed into E. coli BL21 (DE3)
competent cells and plated on LB-agar plate containing 30µg/ml chloramphenicol and
was incubated overnight at 37 oC. The transformants were emulsified and stored as 20%
glycerol frozen stocks at -80 oC. The libraries were restreaked on an LB-Agar plate with
chloramphenicol antibiotic.
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Table 3.1 List of Primers used for Saturation Mutagenesis

a
b

Primersa

Sequenceb

Ser330X

5’- GGTGGTGTGTTCGGTNNSCTGATGTCTACGCCG -3’

Ser333X

5’- GGTTCCCTGATGNNSACGCCGATCATCAACCCG -3’

His348X

5’- GCGCAATTCTGGGTATGNNSGCTATCAAAG -3’

X represents any amino acid.
N refers to an equal mixture of A, T, G and C; S refers to an equal mixture of G and C.

E2o libraries (Ser330X, Ser333X and His348X) were screened. First, a sample
from the frozen stock of each of the E2-libraries was applied onto an LB-Agar plate
containing 30 µg/ml chloramphenicol. Next, approximately 270 colonies of each library
were picked onto a 96-well plate (200 µl volume) containing LB media with 30 µg/ml
chloramphenicol and shaken overnight at 250 rpm and 37 oC. The first column was
inoculated with wt-E2o single colonies as control. The plates were covered with
breathable cover films to minimize evaporation. Next, the plate was replicated into 96
deep-well plate (2 ml volume) containing 1 ml LB media, 30 µg/ml chloramphenicol, 0.3
mM lipoic acid and 1 mM IPTG. This master plate was stored at -80 oC. The plates were
induced for 16 h at 250 rpm, at 37 oC in triplicates. The OD600nm/µl was normalized for
the culture and the cells were harvested by centrifugation at 2000 g for 15 min at 4 oC.
The residual supernatant was discarded, and the cell pellets containing the expressed
mutant proteins were frozen at -20 oC.
The cell pellets were resuspended in 300 µl lysis buffer (20 mM KH2PO4, 0.2 M
NaCl, 1 mM DTT, 1 mM benzamidine-HCl), protease inhibitor (2 tablets/50 ml),
lysozyme (1 mg/ml), DNAse (0.1mg/ml) and incubated for 40 min at 37

o

C. After

incubation, the suspension was centrifuged at 2000 g for 25 min at 4 oC. The supernatant
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was used as the E2-lysate for assembly and the pellet was discarded. All subsequent steps
were performed on ice.
The complex was assembled by the following procedure. E1o and E3 expression
was previously described and cell lysates were used in the assay[13,18]. The expression
was based on cell density and normalized. The lysates of E1o, E2o and E3 were
reconstituted in a 96 deep-well plate (2 ml volume). The total reaction volume was 300 µl
[240 µl E1:E2:E3 of 1:2:1 (v:v:v); 60 µl buffer (20 mM KH2PO4, 0.2 M NaCl, 1 mM
MgCl2 and 0.2 mM ThDP)]. The first column was E1o-His298Asp/E2o/E3 for control.
The plate was mixed on a plate shaker for 10 min at room temperature and stored on 4 oC
for 30 min.
The activity assay volume was 200 µl. The wells contained 135 µl of assay buffer (0.1 M
Tris-HCl (pH 8.0), 0.15 M NaCl, 1 mM MgCl2, 0.2 mM ThDP, 2.6 mM DTT and 2.5
mM NAD+). Next, 50 µl was transferred from the above lysate solution to each well. The
plates were equilibrated at 30 oC. Then, the reaction was initiated using 0.13 mM CoA
and 10 mM 2-OV. Next, the endpoint (2, 5, 7, and 10 min) was measured at 340 nm at 30
o

C. The plate contents were mixed between readings. Positive clones were identified as

those that were 20 % above the control lane.
A rescreen was performed to eliminate false positives. The positive clones were
streaked on an LB-agar plate containing chloramphenicol (30 µg/ml) from the
corresponding master plate. The plate was incubated for 12 h at 37 oC. 16 colonies were
picked for each positive clone and they were placed into a 96-well plate (200 µl volume)
containing LB media with chloramphenicol (30 µg/ml). Wild-type E2o was used on the
same plate as the control. The activity procedure is similar to the screening assay. The
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His348X library screen identified eight positive clones which were re-screened and
sequenced (Figure 3.3). The positive variants from the preliminary screen was validated
in a rescreen. The graph represents end-point absorbance at 340nm plotted with time.
Each point is an average of 16 E2 colonies for each clone reconstituted with E1o-H298D
and E3. The complex formed with wild-type E2o (E1o-H298D: E2o: E3) was used as
control. The complexes containing E2o-His348Phe, E2o-His348Gln and E2o-His348Tyr
were expressed and purified to verify the screening results. One positive clone was
identified from Ser333X library. Sequencing revealed the variant to be Ser333Met.
However, No positive clones were identified from the Ser330X library that were active
towards 2-OV.

Figure 3.3 Rescreen of E2His348X library.
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3.2.3 Expression and purification of E1o, E2o, E3 and variants
E1o, E2o, E3 and variants were expressed and purified following published procedures
[13,18,90].

3.2.4 Enzyme activity measurements.
Overall activity was measured in triplicate with purified proteins. The kinetic parameters
were determined following published procedures [13,90]. The E1o/E2o/E3 ratios were
optimized at substrate saturation conditions prior to determining the kinetic parameters of
the OGDHc variant complexes. The mass ratios (µg: µg: µg) for E1o-His298Asp:E2oHis348Phe:E3,

E1o-His298Asp:E2o-His348Gln:E3,

and

E1o-His298Asp:E2o-

His348Tyr:E3, were 1:8:1, while E1o-His298Asp:E2o-Ser333Met:E3 was 1:10:1.

3.2.5 Modelling of solvent accessible surface
The solvent accessible substrate binding channel was generated by the 3 V (VossVolume-Voxelator) server. First, the structure of E2o CDo was prepared by deleting all
non-standard and non-complexed residues using the UCSF Chimera tool. This structure
was entered as input in the 3V server. The outer probe radius was set to 9 Å and the inner
probe radius was set to 1.5 Å. The final solvent accessible volume was generated as a
solid surface accessing into the protein substrate binding pocket. The server also gives
output about the volume and surface area of the binding channel [131]. This is an mrc file
extension, which is viewable in the UCSF Chimera software.
Further, the Rotamer tool in Chimera was used to generate the mutants in the E2o
active site. The amino acid substitution calculations provide results with a number of
orientations of the side chain with the corresponding probability. The orientation with the
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maximum probability in the active site pocket without the substrate bound is chosen. This
conformer is further overlaid with the wild-type E2o chain, to generate any visual
changes in the active site pocket.

3.2.6 Receptor-ligand docking of substrate into E2oCD with Chimera
Ligand
The ligand (S8-succinyl dihydrolipoamide) was created using Chemdraw Ultra 12.0
software. Next, the translated canonical SMILE string of the 2D structure was used to
generate a 3D structure of the ligand with a -1 charge. This structure was saved as mol2
file and used as ligand for docking.
Receptor
The receptor (E2oCD) was obtained from RCSB PDB (1c4t). First, the nonstandard and
unbound solvent atoms were removed from the structure. Then, the Dockprep tool was
used on the receptor to minimize the structure. The necessary hydrogens and charges
were added. This structure was saved into a new PDB file and used for docking.
Docking
The Autdock Vina plugin was used to perform the docking. The search volume was set
for a cube with edge length 15Å. The cube occupied the proposed active site pocket. The
docking results returned 10 possible orientations of the ligand with the receptor. The
orientations were scored based on the energy (kcal/mol) and RMSD values. The
orientation of the ligand with the highest score with respect to the receptor was chosen.
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3.2.7 Enzymatic synthesis of the butyryl-CoA by OGDHc assembled from
His298Asp E1o with E2o variants with substitutions in the trans-thiolacylation
active center, and with E3
For enzymatic synthesis of the butyryl-CoA, the E1oHis298Asp was reconstituted with
E2o variant (His348Phe, His348Tyr, His348Gln or Ser333Met) and E3. The complex
was assembled in 0.1 mL buffer containing 0.1M Tris (pH 7.5)0.3M NH4Cl, 0.5 mM
ThDP and 2.0 mM MgCl2. For OGDHc assembly, the His298Asp E1o (0.035 mg) was
mixed with the E2o variant (0.24 mg) and E3 (0.059 mg) at a mass ratio of 1: 6.9: 1.7, a
ratio that was selected from kinetic experiments where NADH production by the variant
complexes from 2-OV was measured at OD340. After 30 min of incubation of the
assembled components at 25 oC, the reaction medium containing 0.1M Tris.HCl (pH 8.0),
0.5 mM ThDP, 2.0 mM MgCl2, 2.6 mM DTT and 2.5 mM NAD+ was added to each
reaction mixture to a total volume of 0.4 mL. Next, 2-OV (4 mM final concentration) was
added to each reaction mixture followed by equilibration for 1 min at 30 oC in a
thermomixer (Eppendorf). The enzymatic reaction was initiated by addition of CoA (300
µM final concentration). After one h or overnight incubation at 30 oC, the samples were
acidified to pH 2.0 by additon of 2.5% trifluoroacetic acid (TFA) to a final concentration
of 0.1%

and were filtered through a 10-kDa membrane (Amicon Ultra-0.5 mL

centrifugal filters, Millipore Sigma) to separate proteins from the reaction mixture.
The CoA esters were purified by solid phase extraction with Sep-Pak® Vac tC18
cartridges (Waters) equilibrated with 0.1% TFA[132]. Briefly, the cartridges were
washed with 3 vol of 0.1% TFA (v/v) and CoA esters were eluted with 0.1% TFA
containing 50% acetonitrile (v/v). Solvent was partially removed by centrifugation on a
Speed-Vac concentrator. The samples were concentrated to a volume of ~100 µL.
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3.2.8 Analysis of product using MALDI TOF/TOF Mass Spectrometry
Butyryl-CoA (Sigma Aldrich) and CoA (Sigma Aldrich) were used as external standards.
The matrix was CHCA (α-cyano-4-hydroxycinnamic acid from Sigma) which was
dissolved in 70% acetonitrile/0.1% TFA. Approximately 1 µL of the sample was
withdrawn and was mixed with1 µL of α-cyano-4-hydroxycinnamic acid matrix in the
tube and then 1µL of the mixture was spotted on the plate. The samples were analyzed
with a 355 nm laser in the negative mode on the ultrafleXtreme MALDI TOF/TOF
spectrometer (Bruker Daltonics, Bremen, Germany). For each spectrum, 5 subspectra
with 400 laser shots with 400 Hz frequency were acquired. The spectra were analyzed
using flexAnalysis 3.0 software (Bruker Dlatonics, Bremen, Germany) and were
smoothed using by the Savitzky-Golay algorithm after the baseline subtraction.

3.3 Results and Discussion
This is the first report in which the 2-oxoglutarate dehydrogenase complex is converted
into a 2-oxo aliphatic dehydrogenase complex by consecutive engineering of the E1o and
E2o components. The natural substrate for OGDHc is 2-OG, which contains a terminal
carboxylate group. Variants of the multienzyme complex were screened for overall
activity towards 2-OV, which has a terminal methyl group (Figure 3.1). We were able to
bypass the three stages of substrate recognition, namely the E1o active site, the lipoyl
domain of E2o, and the catalytic domain of E2o.
The E2o variants were overexpressed, purified, and assembled with E1o-His298Asp
and E3. The kinetic parameters were evaluated for the 2-OV. Wild-type E1o/E2o/E3
does not show detectable overall activity (NADH production) towards 2-OV. Previously,
E1o-His298Asp was demonstrated to be active for 2-OV in an E1o-specific assay.
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However, E1o-His298Asp/E2o/E3 does not show overall activity towards 2-OV[13].
This indicated additional engineering at E2o was required for altering substrate
specificity in the overall reaction. The residues Ser330, Ser333, and His348 were
proposed to be important in substrate recognition in E2o[16]. Hence, saturation
mutagenesis libraries of these residues were constructed (E2-Ser330X, E2-Ser333X or
E2-His348X) and assembled with E1o-His298Asp and E3, and the overall activity was
screened with 2-OV. Positive clones were identified that displayed approximately 20%
activity above the wild-type control for 2-OV. The E2o variants with the His348Phe,
His348Tyr, His348Gln, or Ser333Met substitution were identified in the screen to be
active towards 2-OV in the overall activity assay (NADH formation).

3.3.1 Computational
measurements

analysis

of

substrate

channel

and

surface-volume

There are three proposed binding sites in the trimer. Each site is formed at the interface
of two monomers[9,16]. For example, the cyan and green E2o CD monomers together
form the substrate binding pocket and the water accessible volume is represented in solid
magenta (Figure 3.4). The substrate accessible volume was computed by rolling a 1.5 Å
sphere, and it is represented in a magenta solid (Figure 3.4) [131]. The volume was
determined to be 2265 Å3 of the wt-E2o CD (Figure 3.4A). E2o His348Phe and
His348Tyr have similar volume when compared to wt-E2o CD (Figure 3.4B and 3.4D).
On the other hand, the E2o CD His348Gln and Ser333Met variants have smaller volumes
of 18 Å3 and 90 Å3, respectively (Figure 3.4C and 3.4E).
The ligand S8-succinyl dihydrolipoamide (SLM) was modelled substrate binding
channel of E2oCD and its variants. The H-bond distances were calculated between the
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amino acid side chains of residue lining the active site pocket of the receptors (E2oCD)
and terminal carboxylate of SLM. The wild type E2oCD was docked with SLM as
control (Figure 3.5A).
It has been proposed that the His348 and Ser333 residues are able to identify the
terminal carboxylate of SLM by forming a H-bond [16]. The wild type docking results
show that the distances of the carboxylate of SLM and the His348-N2 and Ser333-0H is
3.2 Å and 2.7 Å, respectively (Table 3.2). These distances fall under moderately strong
H-bond category.
The side chains for E2oCD-His348Tyr side chains of residues are 3.4 and 3.0 Å for
Tyr348 and Ser333, respectively (Figure 3.5D, Table 3.2). Also, kinetic experiment
results show that E2oCD-His348Tyr is the most active variant (kcat/Km: 38.5% with
respect to the wt-E2oCD) towards 2-OG. This variant has similar hydrogen bond
distances and binding site volume. Hence, it is most active for 2-OG.
The side chains for E2oCD-His348Phe are 4.6 and 3.1 Å for Phe348 and Ser333,
respectively (Figure 3.5B, Table 3.2). The Van der Waals volume of Phe side chain (135
Å3) is slightly larger than His (118 Å3). Phe fulfills a volume constraint, which is
accompanied by lower catalytic efficiency (28% of wt-E2oCD).
The side chains for E2oCD-Ser333Met side chains are 3.5 and 4.0 Å for His348 and
Met333, respectively (Figure 3.5E, Table 3.2). Moreover, the side chains for E2oCDHis348Gln are 3.4 and 4.7 Å for Gln348 and Ser333, respectively (Figure 3.5C, Table
3.2). The substrate-channel volumes decrease by 90 Å3 and 18 Å3 for both Ser333Met
and His348Gln variants. This decrease is attributed to a change in the orientations of the
amino acids side chains at position 333 for both the mutants which is reflected in a poor
interaction with the substrate (Table 3.2). A cumulative unfavorable environment leads to
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a decrease in catalytic efficiency (24% and 17% w.r.t. wt-E2oCD) for both Ser333Met
and His348Gln variants.

Table 3.2 Comparison of E2oCD Amino Acid Side Chain Distances with Catalytic
Efficiency towards 2-OG
E2oCD substitution
none
His348Tyr
His348Phe
Ser333Met
His348Gln

kcat/Km, 2-OG
(M-1s-1)
875 x 103
(100%)
337.5 x 103
(38.5%)
244 x 103
(28%)
210 x 103
(24%)
149 x 103
(17%)

Residue
348a (Å)
3.2

Residue 333b
(Å)
2.7

3.4

3.0

4.6

3.1

3.5

4.0

3.4

4.7

Denotes the distance between terminal carboxylate of S(8)-succinyl dihydrolipoamide and side chain of
the respective residue at position 348.
b
Denotes the distance between terminal carboxylate of S(8)-succinyl dihydrolipoamide and side chain of
the respective residue at position 348.
a
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Figure 3.4 The solvent-accessible substrate channel modelled into the trimeric E2oCD.

The substrate channel is shown in magenta. The trimer is represented by three different ribbon colors (red,
green and cyan). Only one of the available three channels have been represented. S330, S333 and H348 are
depicted as grey spheres. A. Wild type; B.His348Phe; C. His348Gln; D. His348Tyr; E. Ser333Met.
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Figure 3.5 The active-site binding pocket of the E2oCD trimer and its variants docked
with the substrate is represented.
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S8-succinyl dihydrolipoamide (ligand) was docked into the active site pocket of the
E2oCD (receptor) and variants: A. wildtype E2oCD B. E2oCD-His348Phe C. E2oCDHis348Gln D. E2oCD-His348Tyr E. E2oCD-Ser333Met. The docking calculations were
performed with AutoDock Vina v.1.1.2

using Chimera to visualize [129,130]. The

distances between the terminal carboxylate oxygen of S8- succinyl dihydrolipoamide and
nearest the side-chain atom of the corresponding amino acid receptor has been shown.

3.3.2 Assembly of E1o-His298Asp/E2o-variants/E3 complex active with 2-OV
The overall activity ratio for the [E1o-His298Asp/E2o-His348Gln/E3]2-OV, [E1oHis298Asp/E2o-Ser333Met/E3]2-OV,

[E1o-His298Asp/E2o-His348Tyr/E3]2-OV,

[E1o-

His298Asp/ E2o-His348Phe/E3]2-OV, were 1.8%, 2.1%,, 3.0% and 5.6%, respectively,
when compared to [E1o-His298Asp/E2o/E3]2-OG (Table 3.3). E1o-His298Asp and E3
assembled with E2- His348Phe, E2- His348Gln, or E2- His348Tyr had a Km between
0.01- 0.05 mM (Figures 3.6 a,b; 3.7a,b; 3.8a,b and 3.9a,b). On the other hand, the Km for
E1o-His298Asp/E2o/E3 could not be determined because it has no activity towards 2OV.
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Table 3.3 Kinetic Characterization of the Different Complexes with Substrates 2Oxoglutaric Acid, 2-Oxovaleric Acid and 2-Oxo-5-Hexenoic Acid (continued)
2-oxoglutaric acid
E2 substitution

Km
(mM)
0.04 + 0.01

kcat
(s-1)
35

kcat/Km
(M-1s-1)
875 x 103

noneb

Overall activity
(µmol/min/mg E1)
18.2 + 0.6
(100%)
5.35 + 0.11 (29.4%)

0.03 + 0.007

21.1

703.3 x 103

His348Pheb

2.06 + 0.04 (11.3%)

0.03 + 0.011

7.32

244 x 103

His348Glnb

2.94 + 0.1 (16.1%)

0.07 + 0.01

10.45

149.3 x 103

His348Tyrb

1.90 + 0.02 (10.6%)

0.02 + 0.005

6.75

338 x 103

Ser333Metb

2.37 + 0.03 (13.02%)

0.042 + 0.01

8.4

210 x 103

nonea

2-oxovaleric acid
E2 substitution
nonea

Overall activity
(µmol/min/mg E1)
No activity detected

Km
(mM)
-

kcat
(s-1)
-

kcat/Km
(M-1s-1)
-

noneb

No activity detected

-

-

-

His348Pheb

0.30 + 0.1

0.01 + 0.004

0.81

81 x 103

His348Glnb

0.096 + 0.03

0.05 + 0.01

0.34

6.8 x 103

His348Tyrb

0.161 + 0.02

0.01 + 0.007

0.57

57 x 103

Ser333Metb

0.107 + 0.006

0.08 + 0.012

0.38

4.7 x 103
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Table 3.3 (continued) Kinetic Characterization of the Different Complexes with
Substrates 2-Oxoglutaric Acid, 2-Oxovaleric Acid and 2-Oxo-5-Hexenoic Acid
2-oxo-5-hexenoic acid
E2 substitution
nonea

Overall activity
(µmol/min/mg E1)
No activity detected

Km
(mM)
-

kcat
(s-1)
-

kcat/Km
(M-1s-1)
-

noneb

No activity detected

-

-

-

His348Pheb

0.279 + 0.0012

0.5 + 0.14

0.99

1.98 x 103

His348Glnb

0.182 + 0.005

1.1 + 0.2

0.65

0.59 x 103

His348Tyrb

0.243 + 0.033

0.73 + 0.25

0.86

1.17 x 103

Ser333Metb

0.50 + 0.12

0.11 + 0.023

1.68

15.3 x 103

Wild type E1o/E2o/E3 in a mass ratio of 1:1:1 (µg: µg: µg).
The mutant complex is comprised of E1oHis298Asp, indicated E2o-X (X=Phe, Gln, Tyr or, Met) and E3
with a mass ratio of approximately 1:8:1 (µg: µg: µg). Activity was calculated per mg of E1His298Asp.
a

b
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Figure 3.6 Michaelis Menten curves for the overall activity of the complex constituted of
E1oHis298Asp:E2oHis348Phe:E3 in a mass ratio of 1:8:1 (µg: µg: µg).

The Y axis is represented by the rate of reaction shown by slope/min at absorbance 340nm. The X axis is
represented by the corresponding substrate. For plot a. substrate 2-oxoglutarate is used. For plot b. substrate
2-oxovalerate is used and for plot c. substrate 2-oxo-5-hexenoic acid is used.
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Figure 3.7 Michaelis Menten curves for the overall activity of the complex constituted of
E1oHis298Asp:E2oHis348Gln:E3 in a mass ratio of 1:8:1 (µg: µg: µg).
The Y axis is represented by the rate of reaction shown by slope/min at absorbance 340nm. The X axis is
represented by the corresponding substrate. For plot a. substrate 2-oxoglutarate is used. For plot b. substrate
2-oxovalerate is used and for plot c. substrate 2-oxo-5-hexenoic acid is used.
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Figure 3.8 Michaelis Menten curves for the overall activity of the complex constituted of
E1oHis298Asp:E2oHis348Tyr:E3 in a mass ratio of 1:8:1 (µg: µg: µg).
The Y axis is represented by the rate of reaction shown by slope/min at absorbance 340nm. The X axis is
represented by the corresponding substrate. For plot a. substrate 2-oxoglutarate is used. For plot b. substrate
2-oxovalerate is used and for plot c. substrate 2-oxo-5-hexenoic acid is used.
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Figure 3.9 Michaelis Menten curves for the overall activity of the complex constituted of
E1oHis298Asp:E2oSer333Met:E3 in a mass ratio of 1:10:1 (µg: µg: µg).
The Y axis is represented by the rate of reaction shown by slope/min at absorbance 340nm. The X axis is
represented by the corresponding substrate. For plot a. substrate 2-oxoglutarate is used. For plot b. substrate
2-oxovalerate is used and for plot c. substrate 2-oxo-5-hexenoic acid is used.
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The kcat/Km was 81.0, 57.0, 6.8, and 4.7 mM-1. s-1 for [E1-His298Asp/E2-X/E3] (X =
His348Phe, His348Tyr, His348Gln, or Ser333Met) with 2-OV, respectively.

The

residue histidine 348 is conserved in a broad range of species [16,17]. This residue was
proposed to interact with the distal carboxylate of 2-OG for substrate recognition. It
could be predicted that a hydrophobic amino acid substitution is required for 2-OV
recognition and E2-His348Phe was most active towards 2-OV.

The phenylalanine

substitution does not alter the volume. It may enhance favorable hydrophobic interactions
with the distal –CH3 group of 2-OV to accommodate the substrate in the pocket (Figures
3.4B, 3.5B and 3.10A). The tyrosine amino acid substitution does not alter the solvent
accessible volume. However, the hydrophobic character of the phenol ring furnishes
complementary interactions with 2-OV that are not available with histidine. The histidine
and glutamine have similar size, which are 114 and 118 Å, respectively. The His348Gln
has a smaller solvent accessible volume than wt-E2o CD (Figures 3.4C, 3.5C and 3.10B).
It is possible that a reduced pocket size favors the accommodation of the smaller 2-OV.
Furthermore, the hydroxyl group of serine at position 333 has been proposed to H-bond
with the distal carboxylate of succinyl dihydrolipamide [16].

Finally, similar to

His348Gln, the Ser333Met substitution results in a smaller volume for 2-OV. Hence,
methionine can interact favorably with the distal -CH3 (Figure 3.4E, 3.5E and 3.10D).
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Figure 3.10 Substrate binding pocket of 2-OV binding variants.
substitution is superimposed over the wild-type residue.

The amino acid

Wt-E2o is represented by cyan ribbon. The orange ribbon represents the mutants A. H348F B. H348Q C.
H348Y and D. S333M (PDB ID 1c4t).

The variant complexes show substrate inhibition with higher concentrations of 2OV (Figure 3.11), the His348Gln < His348Phe < Ser 333Met. The complex assembled
with E2-Ser333Met shows maximum inhibition with 2-OV, while the His348Gln variant
shows the least inhibition. The complex assembled with E2o-His348Tyr, however,
remained unaffected by higher concentrations of 2-OV.
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Figure 3.11 Substrate inhibition kinetics of the 2-oxovalerate dehydrogenase complexes
consisting of E2o variants His348Phe, His348Gln and Ser333Met in overall activity with
2-oxovalerate.
3.3.3 E1o-His298Asp/E2-variants/E3 complexes active with 2-OHe
The engineered 2-oxo aliphatic acid dehydrogenase was evaluated to accept alternate
functionalized aliphatic substrates. The kinetic parameters were determined for 2-OHe.
This substrate is the next higher homolog of 2-OV, which contains a terminal alkene
(Figure 3.1).

The 2-OHe contains an alkene substituent that is useful for potential

functionalization to increase subsequent product diversity. Similarly to 2-OV, no overall
activity was detectable with wt-OGDHc and complex reconstituted with E1oHis298Asp/E2o/E3 and 2-OHe. The kcat/Km was 15.3, 1.98, 1.17, and 0.59 mM-1 . s-1 for
Ser333Met, His348Phe, His348Tyr and His348Gln, respectively (Figures 3.6c, 3.7c, 3.8c,
3.9c).

Ser333Met variant is the most active. This is expected because methionine

provides a small and hydrophobic pocket. On the other hand, the Phe, Tyr, and Gln
substitutions at position 348 may fulfill a space constraint. The complexes assembled as
[E1o-His298Asp/E2o-His348Gln/E3]2-OHe,

[E1o-His298Asp/E2o-His348Tyr/E3]2-OHe,
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[E1o-His298Asp/E2o-His348Phe/E3]2-OHe, and [E1o-His298Asp/E2o-Ser333Met/E3]2OHe

when compared to [E1o-His298Asp/E2o/E3]2-OG, displayed overall activities of 3.4%,

4.54%, 5.2%, and 9.3%, respectively (Table 3.3).

3.3.4 The activity of reconstituted E1o-His298Asp/E2-variants/E3 active with 2-OG
The OGDHc variants acquired new substrate specificity for aliphatic substrates and it
also retained activity towards 2-OG. The kinetic parameters were compared with wtOGDHc with the variant complexes and 2-OG. The kcat/Km was 1.2-fold greater for wtOGDHc compared to E1-His298Asp/E2o/E3. The variant’s reduced catalytic efficiency
is mainly due to the reduction of kcat (Table 3.3). Next, E1-His298Asp/E3 reconstituted
with E2o-His348Tyr, His348Phe, Ser333Met or His348Gln was considered and the
kcat/Km was decreased by 2.5, 3.6, 4.1 and 5.9-fold relative to wt-OGDHc, respectively.

The decrease was attributed to reduction of kcat.
Next, the E1o-His298Asp and E3 was assembled with E2o-His348Phe, E2oHis348Gln, E2o-His348Tyr and E2o-Ser333Met.

The overall activity was 11.3%,

16.1%, 10.6% and 13% compared to wt-OGDHc towards 2-OG (Table 3.3), respectively.
Volume calculations indicate that the pocket size does not change for His to Tyr or
Phe substitutions at position 348 (Figures 3.4A, 3.4B, 3.4D). Histidine to tyrosine is a
conservative substitution, and it is the most active variant towards 2-OG[133]. The
tyrosine hydroxyl group can interact with the terminal carboxylate of 2-OG. The Phe
residue could only fulfill a volume requirement. The Met or Gln substitutions lead to a
smaller binding pocket, which may lead to unfavorable steric interaction with 2-OG. In
addition, the hydrophobic side chain of Met leads to detrimental interactions with the
carboxylate of 2-OG.
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It is clear that the amino acid substitutions identified by our experiments could not
be predicted. For example, Phe is one the most hydrophobic amino acids. However, 2OG remains active with E2o His348Phe.

In fact, the catalytic efficiency is only

decreased by 3.6-fold [13,134].

3.3.5 E1o specific activity towards 2-OG, 2-OV, and 2-OHe
The E1o-specific activity ratio for wt-E1o2-OV : wt-E1o2-OG, wt-E1o2-OHe : wt-E1o2-OG, E1His298Asp2-OV ; wt-E1o2-OG, and E1-His298Asp2-OHe : wt-E1o2-OG are 5.5, 2.0, 17.4, and
5.4%, respectively (Table 3.4). The E2o variants were assembled with E1o-His298Asp
and E3 to form the engineered complexes. The overall activity (NADH) for this complex
was determined with 2-OG, 2-OV and 2-OHe. First, the overall activity was determined
with

the

natural

substrate,

2-OG.

The

control

complex

formed

by

E1o-

His298Asp/E2o/E3 has approximately 29.4% activity in comparison to wt-OGDHc with
2-OG.
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Table 3.4 E1o-specific Activity and Kinetic Parameters for Various Substrates
Substrate

Wild-type E1o-specific activity
DCPIP activity
Km
kcat
(mM)
(s-1)
(µmol.min-1.mg-1)

kcat/Km
(mM-1s-1)

2-OGa

0.775 + 0.04

0.006 + 0.02

2.7

456.6

2-OVb

0.0429 + 0.004

8.18 + 0.63

0.152

0.0165

2-OHEc

0.0168 + 0.0072

8.01 + 1.9

0.0595

0.0074

Substrate

E1o-specific activity for E1oH298Dd
DCPIP activity
Km
kcat
(mM)
(s-1)
(µmol.min-1.mg-1)

kcat/Km
(mM-1s-1)

2-OGa

0.206 + 0.057

1.87 + 0.81

0.73

0.39

2-OVb

0.135 + 0.04

6.62 + 0.93

0.48

0.0725

2-OHec

0.042 + 0.011

11.1 + 1.3

0.148

0.0134

a

2-OG, 2-oxoglutaric acid; b 2-OV, 2-oxovaleric acid; c 2-OHe, 2-oxo-5-hexenoic acid
d
E1oH298D parameters are determined for four different preparations of the pure enzyme
and the average value of the parameters is shown.
3.3.6 Enzymatic synthesis of butyryl-CoA from 2-oxovalerate
The synthesis of the butyryl-CoA by E1oHis298Asp assembled with each of the E2o
variants and E3 into the corresponding OGDHc was demonstrated and provides strong
evidence that 2-oxovalerate could be a satisfactory substrate for butyryl-CoA synthesis
by some E2o variants, particularly by the E2oHis348Gln variant. Hence, the method
could be employed for bio-based production of butyryl-CoA for E2oHis348Gln and
variants (Figures 3.12-3.17). Table 3.5 summarizes the MALDI TOF/TOF data for all
analyzed E2o variants.
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Figure 3.12 MALDI TOF/TOF detection of the butyryl-CoA formed in the enzymatic
reaction from 2-oxovalerate and CoA by OGDHc assembled from
E1oH298D/E2oH348Q/E3. Both, CoA (m/z = 766.395) and butyryl-CoA (m/z =
836.448) are present on the spectrum. Inset shows an enlarged region of the butyryl-CoA
peak. For experimental conditions, see Materials and Methods section.
Table 3.5 Summary of the MALDI-TOF/TOF data for Butyryl-CoA Detection in the
OGDHc Reaction
E2o variant
assembled with
E1o-H298D and
E3a

CoA
substrate b

Butyryl-CoA
synthesised

Butyryl-CoA /
(CoA + butyryl-CoA)
(the relative peak
heights)

His348Phe
His348Tyr
His348Gln
Ser333Met

m/z = 766.296
m/z = 766.293
m/z = 766.395
m/z = 766.403

m/z = 836.342
m/z = 836.334
m/z = 836.448
m/z = 836.442

0.019 (1.9%)
0.044 (4.4%)
0.221 (22%)
0.066 (6.6%)

Butyryl-CoA synthesis was conducted for ~ 15 h at 30 oC. For His348Phe E2o, data are presented after
one h reaction time since no butyryl-CoA was detected after 15 h of reaction. b The concentrations of CoA
and 2-oxovalerate of 300 µM and 4 mM, respectively were used in the reaction mixture.
a
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Figure 3.13 MALDI TOF/TOF spectrum of the CoA standard (m/z = 766.513).

Figure 3.14 MALDI TOF/TOF spectrum of the butyryl-CoA standard (m/z = 836.489).
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Figure 3.15 MALDI TOF/TOF detection of the butyryl-CoA formed in the enzymatic
reaction from 2-oxovalerate and CoA by OGDHc assembled from E1o-His298Asp, E2oHis348Phe and E3. Both, CoA (m/z = 766.296) and butyryl-CoA (m/z = 836.342) are
present on the spectrum. Inset shows an enlarged region of the butyryl-CoA peak.

Figure 3.16 MALDI TOF/TOF detection of the butyryl-CoA formed in the enzymatic
reaction from 2-oxovalerate and CoA by OGDHc assembled from E1o-His298Asp, E2oHis348Tyr and E3. Both, CoA (m/z = 766.293) and butyryl-CoA (m/z = 836.334) are
present on the spectrum. Inset shows an enlarged region of the butyryl-CoA peak.
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Figure 3.17 MALDI TOF/TOF detection of the butyryl-CoA formed in the enzymatic
reaction from 2-oxovalerate and CoA by OGDHc assembled from E1o-His298Asp, E2oSer333Met and E3. Both, CoA (m/z = 766.403) and butyryl-CoA (m/z = 836.442) are
present on the spectrum. Inset shows an enlarged region of the butyryl-CoA peak.
3.4 Conclusion
The OGDHc is an example of an enzyme in a highly conserved pathway across all
kingdoms. In this study, it was evolved from a 2-oxo acid dehydrogenase to a 2-oxo
aliphatic acid dehydrogenase. This was accomplished by engineering two consecutive
components of the multienzyme complex. The promiscuous variant components were
able to catalyze the reaction with both natural and unnatural substrates. In short, a
generalist could be converted to a new specialist through a negative selection.

For

example, variants could be screened that are not active toward natural substrate while
retaining activity for the non-cognate substrate. Similar to natural evolution, the new
pathway could be engineered to suit particular user-defined goals.

For example,

orthogonal pathways can be engineered from existing pathways. These designed routes
can run in parallel to the existing pathways and can be used for chemical and synthetic
biology [135].
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APPENDIX A
CARBOLIGATION WITH THIAMIN DIPHOSPHATE DEPENDENT ENZYMES

A.1 Introduction
Carboligation is defined as formation of novel C-C bonds [136]. A common reaction
characteristic of ThDP dependent enzymes (glyoxylate carboligase, 1-deoxy-D-xylulose5-phosphate synthase (DXPS), benzaldehyde lyase etc…) involves formation of novel CC bonds or carboligation [137–141]. Previously, the synthetic program using the
carboligation reactions was initiated by Jordan group with various active site
modifications in both yeast pyruvate decarboxylase (yPDC) from Sachharomyces
cerevisae and E1p from pyruvate dehydrogenase complex of Escherichia coli [142–144].
The E1o subunit of OGDHc is known for its decarboxylase activity as the natural
reaction. The function of OGDHc starts with the decarboxylation of 2-OG by E1o to
form the ThDP adduct of succinic semialdehyde (enamine) intermediate (Figure A.1, step
1) [145]. This intermediate is a substrate for the E2oLDo. The succinyl group is
transferred from the E1o active site to LDo followed by the succinyl transferase action at
the CDo. However, in absence of E2 or E3 subunits, the catalytic potential of the central
enamine intermediate has been exploited for the purpose of carboligation. Thus, with the
addition of appropriate acceptors, E1o is able to catalyze the formation of δ-hydroxy-γketo acids [145]. These are important intermediates for organic synthesis. For some
enzymes, carboligation is a natural course of the pathway, while for all 2-oxoacid
decarboxylases, it is a side reaction [142,143,146,147]. ThDP dependent enzymes (E1p,
benzoylformate decarboxylase, etc.), have been demonstrated for carboligation potential
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as industrial biocatalysts. This is due to for their innate promiscuity towards non-natural
substrates and perform carboligation [148]. [44,117,149,150].
The mechanism of carboligation by E1o is similar to that of the ThDP dependent
enzymes. In the first step, C2-ThDP bound intermediate is formed by nucleophilic
addition of the ThDP-ylide to the carbonyl carbon of a donor substrate (Figure A.1).
Next, this step is followed by the decarboxylation reaction, which results in the formation
of an activated carbonyl compound bound to C2 α-ThDP (C2 α-carbanion/enamine)
(Figure A.1). This reaction is common to ThDP dependent class of enzymes.

Figure A.1 E1o catalyzed reaction mechanism of carboligation reaction.

The ThDP acts as an electron sink and the reactivity of the carbonyl carbon atom
adjacent to C2 α -ThDP undergoes an ‘Umpolung’ reaction and this alters the reactivity
of the bound carbonyl carbon from an electrophile to a nucleophile. Also, an enamine95

carbanion, has the properties of an activated aldehyde. Therefore, addition of an acceptor
molecule aldehyde (methyl glyoxal), ketone (ethyl glyoxalate) or keto-acid (2-OV, 2-OG)
(Figure A.2) results in formation of chiral 2-hydroxy ketones (acetoin-like) or hydroxyketoacids (acetolactate-like) [145,151,152].

Figure A.2 Examples acceptor substrates: Ethyl glyoxalate and methyl glyoxal.

This property has been used for chiral synthesis over the years [137,151,153]. E1o
component has been studied for the purpose as well [91,92,147]. E1o has been previously
proved to have a broad substrate range, making it an excellent candidate for protein
engineering [12,13]. Carboligation studies have also been reported by our group with the
E1o component using a 2-keto acid (2-OG, 2-OV and 2-oxo-isovaleric acid)

as a

substrates with various acceptor aldehydes (ethyl glyoxalate and methyl glyoxal) [147].
Thiamin dependent decarboxylases have been engineered to produce enantioselective
carboligase products from amino acid analogs [142,144]. These molecules are potential
lead molecules in drug development pipeline for some of the well-known drugs such as:
the tranquilizer and smoking cessation drug bupropion [154], the anti-allergic drug
cytoxazon [155], and the multidrug-pump inhibitor 5-methoxyhydnocarpin [156].
Carboligase products are also precursors for Alzheimers drugs [142,144].
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The objective of this study is to explore the carboligation properties of the E1o
component of the E.coli 2-oxoglutarate dehydrogenase multienzyme complex (OGDHc)
and its variant His298Asp [147]. In addition, MenD was evaluated for carboligation (vide
infra). A combination of different substrates and acceptor compounds were used to
demonstrate the ability of the enzymes to catalyze carboligation. Studies on several
aliphatic and aromatic substrate-acceptor combination have also been reported for
carboligation reactions catalyzed by E1o [145,157]. The products were characterized by
CD spectroscopy and proton NMR.
MenD

(2-succinyl-5-enolpyruvyl-6-hydroxy-3-cyclohexadiene-1-carboxylate

synthase; EC 2.5.1.64 or 2.2.1.9), is involved in the second step of menaquinone
biosynthesis. MenD catalyzes carboligase reactions as E1o. It catalyzes a ThDP and
Mg+2-dependent 1,4-addition of 2-OG to isochorismate to form SEPHCHC and CO2
(Figure A.3) [158–160]. MenD is the only enzyme known to catalyze the addition of a
ThDP intermediate to the β-carbon of a second substrate [145,161]. This reaction is
similar to the Stetter reaction, which is a 1,4-addition, or conjugate addition, of an
aldehyde to a β-unsaturated compound. A functionally active MenD was expressed and
purified and tested of carboligation reactions.

COOH
OH

O
HOOC

COOH +

MenD

O

O
HOOC

COOH
OH
O

COOH

CO2

isochorismate

COOH
SEPHCHC

Figure A.3 Reaction catalyzed by MenD.
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This work reinforces the versatility of E1o as a valuable chiral synthetic tool. This
is supported by the fact that the enzyme accepts 2-oxoglutaric acid (2-OG), 2-oxoadipic
acid (2-OA), 2-oxo-hexanoic acid (2-OH) and 2-oxo-5-hexenoic (2-OHe) acid as
substrates. Glyoxalate, propanal and butyraldehyde are the acceptor compounds (Figure
A.4).

Figure A.4 Substrates and acceptors for carboligase reaction for E1o and MenD.
A.2 Materials and methods
A.2.1 Materials
Ni-NTA agarose used for protein purification was purchased from GE Healthcare Life
Sciences.

Thiamin

diphosphate

(ThDP),

dithiothreitol

(DTT),

isopropyl-β-D-

thiogalactopyranoside (IPTG), NAD+, coenzyme A (CoA), Micrococcal Nuclease, and
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DNase I, Lyophilized were purchased from Affymetrix USB. E. coli strain JW0715
containing the plasmid pCA24N encoding the OGDHc-E1 (E1o) component [ASKA
clone (-)] was obtained from National Bio Resource Project (NIG, Japan). Sodium
pyruvate, 2,6-dichlorophenolindophenol (DCPIP), 2-oxoglutarate (2-OG), 2-oxovalerate
(2-OV), 2-oxoadipate (2-OA), and glyoxylic acid were purchased from Sigma Aldrich.
Butyraldehyde and propanal were purchased from Acros Organics (part of Thermo Fisher
Scientific). 2-Ketohexanoic acid (2-OH) was purchased from Santa Cruz Biotechnology.
4-Pentenal was purchased from Thermo Fisher Scientific Chemicals.

A.2.2 Expression and purification of wild type E1o human, MenD, wild type E1o
E.coli and its variants
Wild type E1o was obtained from E. coli strain JW0715 harboring the plasmid pCA24N
encoding the OGDHc-E1 (E1o) component. An E. coli AG1 frozen stock harboring the
E1o plasmid was streaked on LB agar plates containing chloramphenicol (100 µg/mL)
and incubated at 37 °C overnight. A single colony was used to inoculate 5 tubes with 10
ml LB containing chloramphenicol (100 µg/mL).
The overnight culture was used to inoculate 4L of LB medium containing
chloramphenicol (30 µg/mL), 1.0 mM thiamin hydrochloride, and 2.0 mM MgCl2. Cells
were grown at 37 oC, 250 rpm till to OD600 reached 0.60-0.70, then 0.50 mM IPTG was
added and cells were grown overnight at 27 oC with shaking. The cells were collected at
4400 g at 4 °C and washed with 20 mM KH2PO4 (pH 7.0) containing 0.15 M NaCl. Cell
pellets were stored at -20 oC until purification.
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Cell Disruption and Purification.
All subsequent steps were carried out at 4 °C. The cells were resuspended in 40-50
ml sonication buffer: 20 mM KH2PO4 (pH 7.4) containing 0.3 M NaCl, 5.0 mM MgCl2,
2.0 mM ThDP, 1.0 mM benzamidine hydrochloride, 25 mM imidazole, and 1.0 mM
PMSF (1.0 mM). Lysozyme was added to a final concentration of 0.60 mg/ml, and cells
were incubated for 20 min on ice. Nuclease and DNase were added at 1,000 units each
and cells were incubated for 20 min on ice. The cells were sonicated for 10 min (20 s
pulsar “on” and 20 s pulsar “off”) using the Sonic Dismembrator Model 550 (Fisher
Scientific). The lysate was centrifuged at 30,000 g at 4 °C for 30 min.
His6-tag wild type E1o or E1o variant were purified by using a His6-tag a Ni
Sepharose 6 Fast Flow Column (GE Healthcare). The column was equilibrated with 150
ml of sonication buffer and 50 ml of cell lysate was applied on the column. The column
was then washed with 10 column volume (CV) of binding buffer containing 20 mM
KH2PO4 (pH 7.5), 0.3 M KCl, 5 mM MgCl2, 2 mM ThDP and 25 mM imidazole
followed by 10 CV of washing buffer containing 20 mM KH2PO4 (pH 7.5), 0.3 M KCl, 5
mM MgCl2, 2 mM ThDP and 50 mM imidazole. The bound proteins were eluted using
elution buffer containing 20 mM KH2PO4 (pH 7.5), 0.3 M KCl, 5 mM MgCl2, 2 mM
ThDP and 200 mM imidazole. Fractions with enzyme were combined, dialyzed against
20 mM KH2PO4 (pH 7.5), 0.30 M KCl, 2.0 mM MgCl2, 0.5 mM ThDP and 1.0 mM
benzamidine hydrochloride. Next, the protein was precipitated by PEG-8000 (50% w/v)
adding 0 – 16% PEG dropwise (~4 ml per 25 ml protein) on ice with stirring for 10-15
minutes. The protein was collected by centrifugation at 15,000 rpm for 20 minutes at 4
o

C. The resulting protein pellet was dissolved in ~0.5 ml of 50 mM KH2PO4 (pH 7.5)

containing 0.4 M ammonium chloride, 1.0 mM MgCl2, 0.2 mM ThDP, and 1.0 mM
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benzamidine hydrochloride.

The purity was confirmed by SDS-PAGE. Wild type E1o

and E1o variants were stored at -80 °C.

A.2.3 CD Spectroscopy for Product Accumulation
CD spectra were recorded on a Chirascan CD Spectrometer (Applied Photophysics,
Leatherhead, U.K.) in 2.4 ml volume with 1 cm path length cell at 30 oC in the near-UV
(270 – 400 nm) wavelength region. E1oec (1.0 mg/ml) in 50 mM KH2PO4 (pH 7.5)
containing 0.15M NaCl, 0.1 mM ThDP, and 0.5 mM MgCl2 was incubated with 5.0 mM
2-OA in the presence of the acceptor 15 mM glyoxylic acid and CD spectra was acquired
at various times to detect product accumulation. E1oh (1.0 mg/ml, 4.4 µM) in 50 mM
KH2PO4 (pH 7.5) containing 0.15M NaCl, 0.2 mM ThDP, and 1.0 mM MgCl2 was
incubated with 2.0 mM 2-OG in the presence of the acceptor 1.0 mM glyoxylic acid and
CD spectra was acquired at various times to detect product accumulation.

A.2.4 Steady State Kinetics of E1oec activity by CD spectroscopy
Time dependent product formation was monitored continuously at 278 nm in the kinetics
mode by CD. A typical reaction mixture in a 2.4 ml cuvette contained 50 mM KH2PO4
(pH 7.5), 0.15 M NaCl, 0.2 mM ThDP, and 1.0 mM MgCl2, and varying concentrations
of glyoxylic acid and fixed concentration of 2-OG or varying concentrations of 2-OA and
fixed concentration of glyoxylic acid. The reaction was started by the addition of 20 µg
of E1oec and was monitored for 500 s at 30 oC. A similar reaction mixture was used with
varying concentrations of 2-OG and fixed concentration of glyoxylic acid with E1oh.
The reaction was started with 10 µg E1oh and was monitored for 500 s at 37 oC. Steady
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state velocities calculated from the linear region of the progress curves were fit to a
hyperbolic Michaelis-Menten plot (Equation A.1).

A.2.5 E1oec specific activity assay with DCPIP
The E1-specific activity of wild type E1o and its variant His298Asp were measured by
monitoring the reduction of DCPIP at 600 nm using a Varian DMS 300
spectrophotometer. The assay medium (1 ml) contained in 50 mM KH2PO4 (pH 7.5), 0.5
mM MgCl2, 0.2 mM ThDP, 0.1 mM DCPIP and 2.0 mM 2-OG or 20.0 mM 2-OV at 30
°C. The reaction was initiated by adding the enzyme (20 μg). One unit of activity is
defined as the amount of DCPIP reduced (μmol/min/mg of E1o). For Km measurement,
similar conditions were used in the presence of substrates [2-OH (2.0 – 20 mM) or 2-oxo5-hexenoic acid (2.0 – 20 mM)]. The observed slope was plotted against [substrate] and
the resulting progress curves were fit to a hyperbolic Michaelis-Menten plot and Km
values were calculated by using Equation A.1.
v = (Vm* xn) / (xn + Kmn)

(A.1)

Where Vm is the maximum slope observed, x is the ligand concentration, n is the Hill
coefficient (Km= S0.5 if n ≠1) and Km is the Michaelis constant for the varied substrate.

A.2.6 Carboligation reaction on an analytical scale
20 mM butyraldehyde and 30 mM 2-oxoglutarate were incubated with 0.7 mg/ml E1oec
in 1.2 mL of reaction buffer (50 mM KH2PO4 (pH 7.5) supplemented with 0.2 M NH4Cl,
0.5 mM ThDP, 2.0 mM MgCl2 and 5% DMSO). The reaction mixture was incubated for
20-24 hours at room temperature and 400 rpm using an orbital shaking platform on a
102

magnetic stirrer. After reaction was completed, circular dichroism (CD) spectroscopy
was performed at 270-450 nm range for product detection. For NMR analysis, the
complete reaction mixture was extracted as follows: (1) 25 µl of 50% formic acid to bring
the pH down to ~3, (2) spin the sample down at 3,000 rpm for 5 minutes to pellet any
protein precipitation and transfer to new tube, (3) add 3 x 300 µl CDCl3 (plus 18 mg
Na2SO4 if strong emulsion forms) and spin down sample at 3,000 rpm for 3 minutes. To
the remaining water layer, CD spectroscopy was again performed to determine amount of
product extracted.
E1o catalyzed reaction conditions: The reactions were performed in 50 mM KH2PO4,
0.1 mM ThDP, 2 mM MgCl2, pH (8.0) at 30 ºC and 300 rpm using a Thermomixer
(Eppendorf). The final concentration of E1o was set to 700 μg/mL.
MenD-catalyzed reaction conditions: The reactions were performed in phosphate buffer
(50 mM potassium phosphate, 0.1 mM ThDP, 2 mM MgCl2·6H2O, pH (8.0) at 30 ºC and
300 rpm using a Thermomixer (Eppendorf). The final concentration of MenD was set to
500 μg/mL.

A.2.7 Expression and purification of MenD
The cells for MenD were grown similarly to E1o with slight modifications. E. coli AG1
cells harboring the MenD plasmid were streaked onto Luria agar plates containing
chloramphenicol (30 μg/mL) and incubated overnight at 37 ˚C. A single colony was
picked and incubated in 20 mL of LB media containing chloramphenicol (30 μg/mL) and
allowed to grow overnight at 37 ˚C with shaking. This was diluted 10X into an 800 mL
LB media kept at 37 °C with constant shaking, containing chloramphenicol (30 μg/mL),
thiamin hydrochloride (1.0 mM), and MgCl2 (1.0 mM). The cultures were induced with
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IPTG (0.5 mM) when the culture attained an OD600 between 0.5 - 0.8. After induction the
cultures were allowed to grow overnight with constant shaking at temperature reduced to
25 ˚C. The cells were later centrifuged and collected at 4,400 g, 4 ˚C, washed with
KH2PO4 (50 mM, pH 7.5) and KCl (0.15 M). The supernatant was discarded and the
pellets stored at -20 ˚C prior to sonication. The cells were resuspended in the sonication
buffer containing KH2PO4 (50 mM, pH 7.5), KCl (0.3 M), ThDP (0.5 mM), MgCl2 (2.0
mM), benzamidine hydrochloride (1.0 mM) and PMSF (1.0 mM in methanol) with
lysozyme (0.6 mg/mL). The sonication and treatment with streptomycin sulfate (0.5%
w/v) was carried out similarly to E1o (2.3.1). The supernatant collected at the end was
applied to a Ni-Sepharose 6 fast column equilibrated with sonication buffer without
lysozyme and PMSF. The loaded protein was subsequently washed with increasing
concentrations of imidazole (30 - 50 mM) containing, KH2PO4 (50 mM, pH 7.5), KCl
(0.3 M). ThDP (0.5 mM), MgCl2 (2.0 mM), benzamidine hydrocloride (1.0 mM) and
eluted using buffer containing imidazole (150 mM). Fraction from the elution were
collected and dialyzed against a dialysis buffer similarly to (2.3.1) with modified KH2PO4
(50 mM) concentration. The protein was filtered using ultrafiltration with a cutoff of 30
kDa.

A.3 Results and Discussion
The studies reported here are an expansion of the previously reported studies done by the
Jordan group adding to the repertory of E1o in chiral synthesis. In addition to the use of
2-oxoacids as substrates, structurally similar carboxylic acids were also tested (Figure
A.4). First, kinetic studies were conducted to verify whether or not the substrates from
Figure A.4 are accepted by E1o. Upon verification that they were in fact accepted
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substrates, overnight carboligation reaction products (Figure A.5) were detected using
CD spectroscopy and 1H NMR.

CD spectroscopy provides valuable information

regarding stereochemistry of the resulting carboligation products. Specifically, the (R)
enantiomer displays a negative CD peak while the (S) enantiomer a positive one all
around 278-285 nm similar to the CD spectrum of acetoin enantiomers.

Figure A.5 Structure and nomenclature of the chiral products produced from the E1o and
variants catalyzed reaction by using variety of acceptors and substrates.
A.3.1 Steady-state kinetics of E1oec by CD spectroscopy or E1o specific activity
assay with DCPIP
First, kinetic studies were conducted to verify if the following substrates are accepted by
E1oec in addition to gathering kinetic data for the acceptor, glyoxylate. Through the use
of either CD spectroscopy, for product accumulation studies or kinetic mode studies, or
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the E1o specific activity assay with DCPIP, various kinetic parameters were obtained
(Table A.1).
Table A.1 E1o Specific Activity and Kinetic Parameters for Various Substrates
and Acceptors
Kinetic Parameters

Substrate or Acceptor

DCPIP Activity
(µmol min-1⋅
mg-1)

2-oxoglutarate

0.775 + 0.04

Glyoxylate

n/ab

2-oxovaleratea

0.135 + 0.04

2-oxoadipate

n/ab

2-ketohexanoic acid

0.020

0.110

4.32 ± 0.50

0.0225

2-oxo-5-hexenoic acid

0.0168 + .007

0.146

8.01 ± 1.9

0.0183

a
b

kcat (s-1)

Km (mM)

kcat/Km
(s-1/mM1
)

2.15 ± 0.10

0.006 + 0.02

456.6

5.71 ± 0.64
0.48 ± 0.06

6.62 + 0.93

0.0725

12.3 ± 1.8

DCPIP assay conducted with E1oec H298D
n/a, not applicable.

Beginning with the E1oec natural substrate, 2-oxoglutarate, and glyoxylate as the
acceptor, the Km value was determined for glyoxylate using a fixed concentration of 2oxoglutarate (Figure A.6).

The kinetic mode on the CD spectroscopy was used to

monitor product formation at 278 nm, with a negative slope indicating the accumulation
of a (-) peak. As shown previously, the negative peak at 278 nm indicated the formation
of the (R)-enantiomer [162].
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Figure A.6 Steady-state kinetics for E1oec with 2-OG and glyoxylate using kinetic mode
on CD spectroscopy (top) and resulting Michaelis-Menten plot (bottom).
Similar experiments were conducted with the substrate 2-oxoadipate, which
demonstrated for the first time that E1oec does in fact accept 2-oxoadipate as a substrate.
First, a wavelength scan was conducted using CD spectroscopy were the carboligation
product peak at (+) 278 nm accumulated over time (Figure A.7, top). The positive peak
does indicate that the resulting carboligation product is the (S)-enantiomer.

Upon

confirmation that E1oec does in fact accept 2-oxoadipate as a substrate, steady state
kinetic data was collected using CD spectroscopy (Figure A.7, middle and bottom).
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Figure A.7 Product detection and kinetics for E1oec with 2-OA and glyoxylate.

(Top) Near-UV CD wavelength scan acquired at the indicated times to detect accumulation of (S)-chiral
carboligation product produced by E1oec (1.0 mg/ml) from 2-oxoadipate (5 mM) and glyoxylate (15 mM)
at 30 oC in 50 mM KH2PO4 (pH 7.5) containing 0.15 M NaCl, 1.0 MgCl2 and 0.1 mM ThDP. (Middle)
Steady-state progress curves of the reaction with E1oec (80 µg) at the indicated concentrations of 2oxoadipate (2-OA) in the presence of 30 mM glyoxylate in 50 mM KH2PO4 (pH 7.5) containing 0.15 M
NaCl, 1.0 MgCl2 and 0.1 mM ThDP. (Bottom) Dependence of the ellipticity at 278 nm on the
concentration of 2-oxoadipate. The data was fit using the hill equation.
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In the case of the carboxylic acid substrates, the E1o specific activity assay with
DCPIP was used where DCPIP acts as the acceptor similar to the carboligation reactions.
The two substrates tested were 2-oxo-hexanoic acid (Figure A.8), containing a saturated
side chain, and 2-oxo-5-hexenoic acid (Figure A.9), containing a terminal alkene
functional group. Both carboxylic acids tested were shown to be accepted by E1oec as
substrates demonstrating once again the versatility of E1o for carboligation reactions.

Figure A.8 E1oec kinetic parameters with 2-ketohexanoic acid from DCPIP activity
assay.

Figure A.9 E1oec kinetic parameters with 2-oxo-5-hexenoic acid from DCPIP activity
assay.
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4.3.2 Carboligation reaction on an analytical scale with E1oec or E1o-His298Asp
Once the 2-oxoacid and carboxylic acid substrates were confirmed to be accepted as
substrates by E1o, glyoxylate and the straight chain aldehydes were introduced as
acceptors to test E1o-catalyzed chiral carboligation reactions. Similar to the analytical
scale production and work up implemented by Muller et al. with some modifications.
First, the 2-oxoacids, 2-OG and 2-OV, were tested with the straight chain
acceptor, butyraldehyde (Figures A.10 and A.11). As determined previously, the E1oec
variant, His298Asp, was shown to accept 2-oxovalerate as a substrate and therefore was
used in these studies. In both cases, the (R)-enantiomer was produced as apparent by the
negative CD peak at 279 nm with 2-OG (Figure A.10) and 2-OV (Figure A.11). Next, the
chiral carboligation product was confirmed through the use of CD spectroscopy as well
as NMR spectroscopy.

First, carboligation product peak was detected by CD

spectroscopy followed by pH adjustment to ~3, conditions under which product
extraction into chloroform could be performed. The 1H NMR spectrum of the resulting
extracted product was then recorded. As all the carboligation products have in common
the CH-OH functional group, they all exhibit a 1H NMR resonance with a proton
chemical shift near 4-5 ppm (Figure A.5).
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Figure A.10 E1oec catalyzed carboligation reaction with 2-oxoglutarate and
butyraldehyde. A 1 mm path length cuvette was used, therefore actual ellipticity is 10x of
that shown.

Figure A.11 E1oec H298D catalyzed carboligation reaction with 2-oxovalerate and
butyraldehyde. A 1 mm path length cuvette was used, therefore actual ellipticity is 10x of
that shown.
In the case of 2-oxoglutarate and butyraldehyde, the 1H NMR spectrum was
obtained to verify the carboligation product (5-hydroxy-4-oxo-octanoic acid) formed
(Figure A.12). The unique proton chemical shift for the CH-OH functional group at ~4.4
ppm (Hc) and ~2.7 ppm (OH) is seen on the NMR spectrum in addition to the other
protons.
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Figure A.12 1H NMR spectrum of E1o-ec catalyzed carboligation product of 2oxoglutarate with butyraldehyde. The large peaks correspond to water (in CDCl3) near
~2.0 ppm and DMSO-d6 near ~2.6 ppm.
Next, the carboxylic acids, 2-ketohexanoic acid and 2-oxo-5-hexenoic acid, were
tested with various acceptors.

The substrate 2-ketohexanoic acid was tested with

glyoxylate, and in this case the (S)-enantiomer was formed verified by the (+) CD peak at
~290 nm (Figure A.13).
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Figure A.13 E1oec catalyzed carboligation reaction with 2-OH & glyoxylate.
Of all the substrates tested, 2-oxo-5-hexenoic acid was of most interest due to the
introduction of the terminal alkene functional group. The resulting carboligation product
with glyoxylate, butyraldehyde, and propanal were confirmed by CD spectroscopy
(Figure A.14). Remarkably, the carboligation product with glyoxylate produced the (S)enantiomer as shown by the positive peak at ~280 nm (Figure A.12, top), while both
butyraldehyde and propanal produced the (R)-enantiomer with a negative peak at 282 nm
(Figure A.12, middle and bottom).
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Figure A.14 CD spectroscopy of E1oec catalyzed carboligation reaction with 2-oxo-5hexenoic acid and various acceptors. (Top) with glyoxylate, (Middle) with
butyraldehyde, and (Bottom) with propanal.

114

4.3.3 Carboligation reaction on an analytical scale with human E1o
In addition to the above work with E1oec, similar initial studies were conducted using
human E1o. For the first time, human E1o was used to catalyze carboligation reactions
and therefore the natural substrate, 2-oxoglutarate, as well as the substrate 2-oxoadipate
were tested with the acceptor glyoxylate. First, the carboligation product produced by 2oxoglutarate and glyoxylate was verified by CD spectroscopy. Similar to the E1oec
results, human E1o produced the (R)-enantiomer as indicated by the (-) 279 nm peak
(Figure A.15).

Figure A.15 Human E1o catalyzed carboligation reaction with 2-oxoglutarate and
glyoxylate. A 1 mm path length cuvette was used, therefore actual ellipticity is 10x of
that shown.
Next, the carboligation product, 2-hydroxy-3-oxohexanedioic acid, was confirmed
by 1H NMR spectroscopy (Figure A.16). Not only is the CH-OH functional group clearly
visible (~4.4 ppm for -CH and ~2.75 ppm for -OH), but the other proton peaks at ~2.7
and 2.5 ppm are also visible. For the first time, the carboligation reaction was
successfully carried out by E1o-h.
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Figure A.16 1H NMR spectrum of E1o-h catalyzed carboligation product of 2oxoglutarate with glyoxylate. The large peaks correspond to water (in CDCl3) near ~1.7
ppm and DMSO-d6 near ~2.6 ppm.
Next, the substrate 2-oxoadipate was used with the acceptor glyoxylate, and in fact
human E1o can catalyze the formation of the carboligation product (Figure A.17). The
most obvious difference is that the product formed is the (S)-enantiomer proving that a
one-carbon difference changes the orientation of the resulting carboligation product. The
NMR spectra of the product has also been shown in Figure A.18.
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Figure A.17 Human E1o catalyzed carboligation reaction with 2-oxoadipate and
glyoxylate. A 1 mm path length cuvette was used, therefore actual ellipticity is 10x of
that shown.

Figure A.18 1H NMR spectrum of E1o-h catalyzed carboligation product of 2-oxoadipate
with glyoxylate. The large peaks correspond to water (in CDCl3) near ~1.8 ppm and
DMSO-d6 near ~2.6 ppm.

117

4.3.4 Comparative carboligation reactions of E1o and MenD
The carboligation reactions were carried out and the presence of a chiral product in
excess was confirmed using CD spectroscopy. The results are summarized in (Table
A.2).

Table A.2 CD Spectra Data for E1o and MenD

Enzyme

Substrate

E1o
(700 μg)

2-oxoglutaratea
c

MenD
(500 μg)

CD278
(mdeg)

Propanalb

-54

Benzaldehydeb

-16

Propanalb

-19

2-oxoglutarate

d

Benzaldehyde

-9

2-oxoglutaratea

Benzaldehydeb

Nd

2-oxo-5-hexenoic acida

Propanal

Nd

2-oxo-5-hexenoic acida

Benzaldehyde

Nd

( 30 mM substrate,
a

Acceptor

b ,d

20 mM acceptor and 10 mM substrate) Nd: not detected
c

The CD was able to detect significant amount of enantiomer at 278 nm. For
reaction between propanal as acceptor and 2-oxoglutarate as substrate with E1o, the
majority of the product obtained was in the (R)-configuration (Figure A.19). The same
was observed for reactions with MenD. When reactions between benzaldehyde as
acceptor and 2-oxoglutarate as substrate were catalyzed using MenD, almost all of the
product obtained was in its (R)-configuration (Figure A.20). For MenD, the best results
were obtained when the substrate concentration was kept close to the enzymes Km value,
above its Km the enzyme suffered saturation inhibition and decreased activity. E1o also
gave similar reactions between benzaldehyde and 2-oxoglutarate. But, the amount of
substrate used did not saturate E1o unlike with MenD. (Km value for 2-oxoglutarate for
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E1o: 0.1 mM; and MenD: 1.5 mM, from the literature [17,46]. For the reactions of 2-oxo5-hexenoic acid with MenD, there was no product detected in CD for reaction with
propanal or benzaldehyde. This adds to the fact that the residues that perform the ThDPdependent decarboxylase activity are conserved in the family and mutations induced at
the conserved domain and/or the hydrophobic chains supporting the active-site pocket
can alter its substrate spectrum and reactivity (Figures A.17, A.18).

Figure A.19 CD spectra of 2-oxoglutarate and propanal.

Figure A.20 CD spectra of 2-oxoglutarate and benzaldehyde.
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APPENDIX B
SEQUENCING RESULTS

Figure B.1 DNA sequencing results with primer E2o-His375Ala.

Figure B.2
mutation.

DNA sequencing alignment of wt-E2o and E2o-His375Ala confirming
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Figure B.3 DNA sequencing results with primer E2o-Thr323Ala.

Figure B.4
mutation.

DNA sequencing alignment of wt-E2o and E2o-Thr323Ala confirming
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Figure B.5 DNA sequencing results with primer E2o-Asp374Ala.

Figure B.6
mutation.

DNA sequencing alignment of wt-E2o and E2o-Asp374Ala confirming
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Figure B.7 DNA sequencing results with primer E2o-Arg376Ala.

Figure B.8
mutation.

DNA sequencing alignment of wt-E2o and E2o-Arg376Ala confirming
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Figure B.9 DNA sequencing results with primer E2o-Arg379Ala.

Figure B.10 DNA sequencing alignment of wt-E2o and E2o-Arg376Ala confirming
mutation.
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Figure B.11 DNA sequencing results with primer E2o-His375Cys.

Figure B.12 DNA sequencing alignment of wt-E2o and E2o- His375Cys confirming
mutation.
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Figure B.13 DNA sequencing results with primer E2o-Thr323Ser.

Figure B.14 DNA sequencing alignment of wt-E2o and E2o-Thr323Ser confirming
mutation.
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Figure B.15 DNA sequencing results with primer E2oCD-His375Ala.

Figure B.16 DNA sequencing alignment of wt-E2o and E2oCD-His375Ala confirming
mutation.
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Figure B.17 DNA sequencing results with primer E2oCD-Asp374Ala.

Figure B.18 DNA sequencing alignment of wt-E2o and E2oCD-Asp374Ala confirming
mutation.
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Figure B.19 DNA sequencing results with primer E2o-His375Asn.

Figure B.20 DNA sequencing alignment of wt-E2o and E2o-His375Asn confirming
mutation.

129

Figure B.21 DNA sequencing results with primer E2o-Asp374Asn.

Figure B.22 DNA sequencing alignment of wt-E2o and E2o-Asp374Asn confirming
mutation.
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Figure B.23 DNA sequencing results for E2o-His348Phe.

Figure B.24 DNA sequencing alignment of wt-E2o and E2o-His348Phe confirming
mutation.
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Figure B.25 DNA sequencing results for E2o-His348Gln.

Figure B.26 DNA sequencing alignment of wt-E2o and E2o-His348Gln confirming
mutation.
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Figure B.27 DNA sequencing results for E2o-His348Gln.

Figure B.28 DNA sequencing alignment of wt-E2o and E2o-His348Tyr confirming
mutation.
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Figure B.29 DNA sequencing results for E2o-His348Gln.

Figure B.30 DNA sequencing alignment of wt-E2o and E2o-Ser333Met confirming
mutation.
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Figure B.31 DNA sequencing results for E2o-His375Trp.

Figure B.32 DNA sequencing alignment of wt-E2o and E2o-His375Trp confirming
mutation.
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Figure B.33 DNA sequencing for E2o-His375Gly.

Figure B.34 DNA sequencing alignment of wt-E2o and E2o-His375Gly confirming
mutation.
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